

Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

Anne-Gaëlle GOUBET^{1,2,3*}, Agathe DUBUISSON^{2,3*}, Arthur GERAUD^{2,4,5}, François-Xavier DANLOS^{2,3}, Safae TERRISSE^{2,3}, Carolina ALVES COSTA SILVA^{2,3}, Damien DRUBAY^{2,6,7}, Lea TOURI^{2,8}, Marion PICARD^{2,3,9}, Marine MAZZENGA^{2,3}, Aymeric SILVIN^{2,3}, Garrett DUNSMORE^{2,3}, Yacine HADDAD^{2,3}, Eugénie PIZZATO^{2,3}, Pierre LY^{2,3}, Caroline FLAMENT^{2,3}, Cléa MELENOTTE^{2,3}, Eric SOLARY^{1,2,10,11}, Michaela FONTENAY^{12,13}, Gabriel GARCIA^{2,14}, Corinne BALLEYGUIER^{2,14}, Nathalie LASSAU^{1,2,14,15}, Markus MAEURER¹⁶, Claudia GRAJEDA-IGLESIAS^{2,3,17,18}, Nitharsshini NIRMALATHASAN^{2,17,18}, Fanny APRAHAMIAN^{2,17,18}, Sylvère DURAND^{2,17,18}, Oliver KEPP^{17,18}, Gladys FERRERE^{2,3}, Cassandra THELEMAQUE^{2,3}, Imran LAHMAR^{2,3}, Jean-Eudes FAHRNER^{2,3}, Lydia MEZIANI^{2,19}, Abdelhakim AHMED-BELKACEM²⁰, Nadia SAÏDANI²¹, Bernard LA SCOLA^{22,23}, Didier RAOULT^{22,23}, Stéphanie GENTILE²⁴, Sébastien CORTAREDONA^{23,25}, Giuseppe IPPOLITO²⁶, Benjamin LELOUVIER²⁷, Alain ROULET²⁷, Fabrice ANDRE^{1,2,4,28}, Fabrice BARLESI^{2,4,29}, Jean-Charles SORIA^{1,2}, Caroline PRADON^{2,30,31}, Emmanuelle GALLOIS^{2,32}, Fanny POMMERET^{2,4}, Emeline COLOMBA^{2,4}, Florent GINHOUX^{33,34,35}, Suzanne KAZANDJIAN³⁶, Arielle ELKRIEF^{36,37}, Bertrand ROUTY^{37,38}, Makoto MIYARA³⁹, Guy GOROCHOV³⁹, Eric DEUTSCH^{1,2,19,40}, Laurence ALBIGES^{1,2,4}, Annabelle STOCLIN^{2,41}, Bertrand GACHOT^{2,42}, Anne FLORIN^{2,8}, Mansouria MERAD^{2,43}, Florian SCOTTE^{2,44}, Souad ASSAAD^{45,46,47}, Guido KROEMER^{2,17,18,48,49,50,51}, Jean-Yves BLAY^{45,46,47}, Aurélien MARABELLE^{2,3,4,5,52}, Frank GRISCELLI^{2,32,53,54,55}, Laurence ZITVOGEL^{1,2,3,52**} & Lisa DEROSA^{1,2,3,4**}.

* Co-first authors have equally contributed to this work.

** Co-last authors have equally contributed to this work.

¹Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

²Gustave Roussy Cancer Campus, Villejuif, France.

³Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.

⁴Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.

⁵Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Villejuif, France.

⁶Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

⁷Institut National de la Santé et de la Recherche Médicale Oncostat, U1018, Equipe labellisée par la Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.

⁸Médecine du travail, Gustave Roussy, Villejuif, France.

⁹Institut Pasteur, Unit Biology and Genetics of the Bacterial Cell Wall, Paris, France; CNRS UMR2001, Paris, France; INSERM, Equipe Avenir, Paris, France.

¹⁰Institut National de la Santé et de la Recherche Médicale, U1287, Gustave Roussy, Villejuif, France.

¹¹Département d'Hématologie, Gustave Roussy, Villejuif, France.

¹²Université de Paris, Institut Cochin, Centre National de la Recherche Scientifique UMR8104, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France.

- 48 ¹³Service d'hématologie biologique, Hôpital Cochin, Assistance Publique – Hôpitaux de
49 Paris.Centre-Université de Paris, Paris, France.
- 50 ¹⁴Département d'Imagerie Médicale, Gustave Roussy, Villejuif, France.
- 51 ¹⁵Biomaps, UMR1281, INSERM, CNRS, CEA, Université Paris Saclay
- 52 ¹⁶Immunotherapy/Immunosurgery, Champalimad foundation, Lisboa, Portugal.
- 53 ¹⁷Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer,
54 Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France,
55 Paris, France.
- 56 ¹⁸Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris
57 Saclay, Villejuif, France.
- 58 ¹⁹Institut National de la Santé et de la Recherche Médicale, U1030, Gustave Roussy, Villejuif,
59 France.
- 60 ²⁰Univ Paris Est Creteil, INSERM U955, IMRB, Creteil, France.
- 61 ²¹Service de maladies infectieuses, Centre Hospitalier de Cornouaille, Quimper, France.
- 62 ²²Aix-Marseille Université, Institut de Recherche pour le Développement, Assistance
63 Publique – Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille,
64 France.
- 65 ²³Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France.
- 66 ²⁴Aix Marseille Univ, School of medicine - La Timone Medical Campus, EA 3279: CEReSS -
67 Health Service Research and Quality of life Center, Marseille, France.
- 68 ²⁵Aix Marseille Université, IRD, AP-HM, SSA, VITROME, Marseille,
69 France.
- 70 ²⁶Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome,
71 Italy.
- 72 ²⁷Vaiomer, Labège, France.
- 73 ²⁸Institut National de la Santé et de la Recherche Médicale, U981, Gustave Roussy, Villejuif,
74 France.
- 75 ²⁹Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
- 76 ³⁰Centre de ressources biologiques, ET-EXTRA, Gustave Roussy, Villejuif, France.
- 77 ³¹Département de Biologie Médicale et Pathologie Médicales, service de biochimie, Gustave
78 Roussy, Villejuif, France.
- 79 ³²Département de Biologie Médicale et Pathologie Médicales, service de microbiologie,
80 Gustave Roussy, Villejuif, France.
- 81 ³³Singapore Immunology Network, Agency for Science, Technology and Research
82 (A*STAR), Singapore.
- 83 ³⁴Shanghai Institute of Immunology, Shanghai, China.
- 84 ³⁵Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Center,
85 Singapore.
- 86 ³⁶Cedar's Cancer Center, McGill University Healthcare Centre, Montreal, QC, Canada.
- 87 ³⁷Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM),
88 Montreal, QC, Canada.
- 89 ³⁸Department of Hematology-Oncology, Centre hospitalier de l'Université de Montréal,
90 Montreal, QC, Canada.
- 91 ³⁹Institut National de la Santé et de la Recherche Médicale, U1135, Centre d'Immunologie et
92 des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique – Hôpitaux de Paris,
93 Paris, France.
- 94 ⁴⁰Département de Radiothérapie, Gustave Roussy, Villejuif, France.
- 95 ⁴¹Service de Réanimation Médicale, Gustave Roussy, Villejuif, France.
- 96 ⁴²Service de Pathologie Infectieuse, Gustave Roussy, Villejuif, France.
- 97 ⁴³Service de médecine aigüe d'urgence en cancérologie, Gustave Roussy, Villejuif, France.

98 ⁴⁴Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy,
99 Villejuif, France.

100 ⁴⁵Centre Léon Bérard, Lyon, France.

101 ⁴⁶Université Claude Bernard, Lyon, France.

102 ⁴⁷Unicancer, Paris, France.

103 ⁴⁸Université de Paris, Paris, France.

104 ⁴⁹Department of Women's and Children's Health, Karolinska Institute, Karolinska University
105 Hospital, Stockholm, Sweden.

106 ⁵⁰Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique – Hôpitaux de
107 Paris, Paris, France.

108 ⁵¹Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences, Suzhou,
109 China.

110 ⁵²Center of clinical investigations BIOTHERIS, Gustave Roussy, Villejuif, France.

111 ⁵³Institut National de la Santé et de la Recherche Médicale – UMR935/UA9, Université Paris-
112 Saclay, Villejuif, France.

113 ⁵⁴INGESTEM National IPSC Infrastructure, Université de Paris-Saclay, Villejuif, France.

114 ⁵⁵Université de Paris, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.

115

116 Corresponding authors:

117 Lisa DEROSA MD, PhD

118 Department of Medical Oncology

119 Head of Clinics of the Microbiome

120 University Paris Saclay,

121 Gustave Roussy Cancer Center

122 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France

123 Telephone: +33 1 42 11 24 51

124 E-mail: lisa.derosa@gustaveroussy.fr

125

126 and Laurence ZITVOGEL, MD, PhD, Full Professor

127 University Paris Saclay,

128 Gustave Roussy Cancer Center,

129 114 rue Edouard Vaillant,

130 94805 Villejuif Cedex, France

131 Telephone: +33 1 42 11 50 41

132 E-mail: laurence.zitvogel@gustaveroussy.fr

133

134 Keywords: cancer, COVID-19, lymphopenia, immunopathology

135

136

137 **Abbreviations in alphabetic order:** ACE2: Angiotensin-Converting Enzyme 2; CD: cluster
138 of differentiation; cMo: classical monocytes; COVID-19: severe coronavirus infectious
139 disease 2019; Ct: Cycle threshold; CR: Clinical Routine; CXCR5: C-X-C chemokine receptor
140 type 5; ECOG: Eastern Cooperative Oncology Group performance status; EM: effector
141 memory cells; Eomes: eomesodermin; FC: fold change; FasL: Fas ligand; GzB: granzyme B;
142 HCW: health care worker; ICOS: Inducible T-cell co-stimulator; ICU: intensive care unit;
143 IFN: Interferon; Ig: Immunoglobulin; IL: interleukin; LVS: long term viral RNA shedding;
144 NK: Natural killer; ; non-cMo: non classical monocytes; NSM: Non-switch Memory; Orf1b:
145 replicase open reading frame 1b; PD: progressive disease; PD-1: programmed cell death 1;
146 PMN: polymorphonuclear cells; RBD: receptor-binding domain; RdRP: RNA-dependent
147 RNA polymerase; RNA: ribonucleic acid; rIL-7: recombinant interleukin 7; RT-qPCR:
148 quantitative reverse transcription-polymerase chain reaction; SARS-CoV-2: severe acute
149 respiratory syndrome coronavirus 2; SD: stable disease; SVS: short term viral RNA shedding;
150 Tc1: cytotoxic T lymphocytes; TCF-1: Transcription factor 1; TFH: T follicular helper cells;
151 TR: Translational Research.
152
153

154 **Abstract**

155

156 **Patients with cancer are at higher risk of severe coronavirus infectious disease 2019**
157 **(COVID-19), but the mechanisms underlying virus-host interactions during cancer**
158 **therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-**
159 **cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome**
160 **coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19⁺), we**
161 **found that malignant disease favors the magnitude and duration of viral RNA shedding**
162 **concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with**
163 **anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical**
164 **immunopathology of severe COVID-19 at the early phase of infection including**
165 **circulation of immature neutrophils, depletion of non-conventional monocytes and a**
166 **general lymphopenia that, however, was accompanied by a rise in plasmablasts,**
167 **activated follicular T helper cells, and non-naive Granzyme B⁺FasL⁺, Eomes^{high}TCF-**
168 **1^{high}, PD-1⁺CD8⁺ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated**
169 **lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA**
170 **shedding, COVID-19 severity and a higher risk of cancer-related death in the first and**
171 **second surge of the pandemic. Lymphocyte loss correlated with significant changes in**
172 **metabolites from the polyamine and biliary salt pathways as well as increased blood**
173 **DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term**
174 **viral carriers. We surmise that cancer therapies may exacerbate the paradoxical**
175 **association between lymphopenia and COVID-19-related immunopathology, and that**
176 **the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated**
177 **death.**

178

179

180

181

182 **Introduction**

183

184

185

186 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel beta-
187 coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-
188 19, resulting in a severe threat to public health and safety worldwide. Because of age, gender,
189 cancer-associated risk factors, metabolic syndrome and side effects induced by their specific
190 therapies (such as cardiomyopathy, systemic immunosuppression and cellular senescence),
191 cancer patients appear more vulnerable to severe infection than individuals without cancer
192 (Derosa et al., 2020). Indeed, a high hospitalization and mortality rates of SARS-CoV-2
193 infection were heralded in patients with malignancy in several studies across distinct
194 geographical sites (Albiges et al., 2020; Assaad et al., 2020; Luo et al., 2020; Ruge et al.,
195 2020). Cancer types, performance status and stage are additional risk factors for severe
196 COVID-19 in this patient population. Patients with hematological, lung and breast cancer
197 have been reported to be more susceptible to hospitalization or death due to COVID-19 as
198 compared to patients with other malignancies (Garassino et al., 2020; Luo et al., 2020;
199 Martín-Moro et al., 2020; Passamonti et al., 2020; Ruge et al., 2020). Patients diagnosed
200 with metastatic cancers are more vulnerable to severe forms of COVID-19 than individuals
201 with localized malignancies (Robilotti et al., 2020). Recent (<3 months) cancer treatments
202 including surgery, chemotherapy and immunotherapy independently contribute to worsen the
203 prognosis of COVID-19 among patients with malignant disease (Albiges et al., 2020; Dai et
204 al., 2020; Luo et al., 2020; Passamonti et al., 2020; Q et al., 2020; Robilotti et al., 2020).

204

205 Here we explored several independent cohorts of cancer patients diagnosed with
206 COVID-19 (1063 patients, 58% with cancer) during the first surge of the pandemic to analyze
207 the dynamics between host (blood immunology, metabolism, metagenomics) and viral
208 parameters and validated the most clinically relevant findings in the second surge of the
209 pandemic. We concluded that virus-induced or -associated lymphopenia that coincided with T
210 cell exhaustion, abnormalities in polyamine and biliary salt pathways and circulation of
211 Enterobacteriaceae and Micrococcaceae bacterial DNA, is a dismal prognosis factor in cancer
212 patients, likely participating in the vicious circle of immunosuppression-associated chronic
213 virus shedding.

213

214 **Results**

215

216 **Prolonged viral shedding and higher viral loads in cancer patients compared with**
217 **cancer free COVID-19⁺ patients**

218

219 To explore the clinical significance of viral and/or immunological parameters in cancer
220 patients, we gathered the data from electronic clinical files from various cancer centers or
221 general hospitals across France and Canada, in order to monitor the magnitude and duration
222 of virus RNA shedding in nasopharyngeal swabs according to cancer (*versus* health care
223 workers (HCW) or COVID-19⁺ cancer free individuals), tumor types (hematological *versus*
224 solid malignancies) and staging (localized, locally advanced, metastatic diseases) (Figure 1A).
225 First, we conducted a prospective epidemiological study named Cancer_FR1_Translational
226 Research (TR) at Gustave Roussy, Villejuif, France, during the first surge of the COVID-19
227 pandemic (from April 10, 2020 to May 11, 2020, NCT04341207) to evaluate the prevalence
228 and severity of COVID-19 in all adult patients under treatment or recently treated for solid
229 tumors or hematological malignancies (Figure S1, Table S1). Our secondary endpoint was the
230 identification of viral, immunological, metabolic and metagenomics blood predictors of
231 severe complications among cancer patients. Clinical characteristics were collected from
232 electronic medical records (Table S1). Nasopharyngeal samples were serially collected at
233 every hospital visit motivated by the cancer management or any symptomatology related to
234 seasonal flu or COVID-19 and transferred to the virology laboratory for SARS-CoV-2-
235 specific quantitative reverse transcription-PCR (RT-qPCR) testing. Out of 473 patients
236 enrolled in Cancer_FR1_TR, 53 (11%) were diagnosed with COVID-19 by RT-qPCR, and
237 this diagnosis was corroborated by a specific serology in 87% cases (Figure S1A). Among the
238 52 patients evaluable for translational research, 37% were males, 60% suffered from at least
239 one of the co-morbidities associated with coronavirus pandemic, such as hypertension (58%)
240 or obesity (21%) (Table S1). Seventy seven percent had an ECOG performance status of 0-1
241 at the time of nasopharyngeal sampling. Twenty one percent of COVID-19 positive cancer
242 patients did not report any symptom of infection, 61% required hospital admission (for any
243 cause or because of COVID-19 aggravation within 28 days after diagnosis) and 11% a
244 transfer to intensive care unit (ICU), culminating with cancer death in 7% of the cases (from
245 undetermined cause, no systematic necropsy) (Figure S1B-G, Table S1). Among patients with
246 cancer diagnosed with COVID-19, 20% were followed up for hematological (as opposed to
247 solid) malignancies and developed more severe symptoms of infection (Figure S1B-G, Table

248 S1). In the Cancer_FR1_TR study, 33%, 21% and 46% presented with localized, locally
249 advanced and metastatic disease, respectively that were equally susceptible to severe COVID-
250 19 (Figure S1F-G).

251 Given that cycle threshold (Ct) values of the first RT-qPCR test may be correlated with the
252 clinical characteristics of the patients (Shlomai et al., 2020; Westblade et al., 2020), we
253 performed a longitudinal follow-up of Ct values by RT-qPCR. We targeted several genes
254 coding for the envelope, the nucleocapsid and/or the replication-transcription complex (RdRP,
255 Orf1a, subgenomic RNA of the SARS-CoV-2 (Corman et al., 2020)(Wölfel et al., 2020)) to
256 assess the duration of the nasopharyngeal SARS-CoV-2 RNA shedding, starting at COVID-
257 19 diagnosis for up to 6 months as per-protocol indications (Figure S2A). The duration of
258 viral shedding was defined as the number of days from the first positive to the first negative
259 RT-qPCR, after longitudinal monitoring with an interval inferior to 40 days, to reduce bias in
260 viral shedding estimation. This time lapse of 40 days corresponded to the median of SARS-
261 CoV-2 virus carriage in the cancer population (Figure 1B-C, Table S1). In parallel, a similar
262 and systematic COVID-19 protocol with longitudinal RT-qPCR testing was applied to health
263 care workers (HCW) at Gustave Roussy. Health care workers had a mean age of 35 years
264 (range: 19-61), were mostly females (male *versus* female: 13% *versus* 87%), and presented
265 with one or two co-morbidities in 27% and 4%, respectively, thereby significantly diverging
266 from the cancer population diagnosed with COVID-19. Starting from 50 COVID-19 positive
267 cancer patients and 100 HCW, we conducted RT-qPCR in 210 and 200 nasopharyngeal
268 swabs, respectively (Figure S2). However, applying the exclusion criteria detailed in Figure
269 S2, we could compare the median length of SARS-CoV-2 RNA detection in 35 cancer
270 patients (Cancer_FR1_TR) and 45 HCW using 168 and 118 samples, respectively. Patients
271 with cancer exhibited prolonged nasopharyngeal RNA virus shedding (Figure 1B, median of
272 40 days (range: 6-137) for patients with cancer compared to 21 days (range: 7-53) for HCW,
273 Figure 1C, log-rank test p -value <0.0001). This difference persisted after adjusting for age,
274 gender and co-morbidities (Cox multivariate analysis, adjusted hazard ratio [95% confidence
275 interval] =2.88 [1.42;5/85], $p=0.00291$, Figure 1C). To further validate the differences
276 observed in the duration of viral RNA shedding between Cancer_FR1_TR and HCW, we
277 analyzed another cohort of patients diagnosed with COVID-19 in a general hospital from
278 Southern France and paired - in a case-control study - 175 cancer patients (with a history of
279 cancer or currently treated with cancer (Table S1)) with 350 cancer free individuals based on
280 age, gender, comorbidities and COVID-19 severity (FR2_Case-Control, Cancer and Non-
281 Cancer) (Figure 1A, Table S1). Here again, there was a prolonged length of RT-qPCR

282 positivity in cancer individuals compared with cancer free COVID-19 patients (8 days *versus*
283 6 days, log-rank test *p*-value, $p=0.03$), taking into account that >70% were treated with
284 hydroxychloroquine and azithromycine, a combination regimen reducing viral shedding
285 (Lagier et al., 2020). Moreover, the proportion of patients with a viral shedding above 16 days
286 (corresponding to the 90th percentile of the viral shedding in cancer-free patients) was higher
287 in cancer patients (Figure 1D, $p<0.0015$). A second independent validation was achieved in a
288 third series of 66 patients with cancer extracted from a cohort of 252 cancer individuals living
289 in Canada and diagnosed with COVID-19 (Cancer_CA), for whom a longitudinal SARS-
290 CoV-2-specific RT-qPCR (using *Orf1* and *E* gene probe sets (Boutin et al., 2020)) follow-up
291 had been carried out (Elkrief et al., 2020) (Figure 1A, Table S1). Here again, we observed that
292 26% of cancer patients were still PCR positive after 40 days from diagnosis by RT-qPCR
293 (Figure 1E). Such a long term PCR detection of viral RNA could indicate stable subgenomic
294 RNA contained within double membrane vesicles or presence of a replicative mucosal viral
295 strain. Hence, we confirmed in three independent series of cancer patients a prolongation of
296 RNA virus shedding previously described in case reports in hematological or immuno-
297 compromised patients (Avanzato et al., 2020; Aydillo et al., 2020; Choi et al., 2020;
298 Helleberg et al., 2020).

299
300 Hence, we focused on the differential characteristics of cancer patients presenting with Long
301 term Viral RNA Shedding (LVS), defined by a positive RT-qPCR duration ≥ 40 days (median
302 of RT-qPCR duration in Cancer_FR1_TR (Figure 1C)), compared to those experiencing Short
303 term Viral RNA Shedding (SVS), defined by a positive RT-qPCR duration < 40 days
304 henceforth (Table S1). The increased susceptibility to develop a LVS was independent of
305 initial symptomatology, observed in 33% of Canadian (CA) to 40% of French (FR1_TR)
306 asymptomatic and 27% (CA) to 56% (FR1_TR) of symptomatic cancer patients (Figure 1F).
307 There was a higher propensity to LVS in hematological malignancies compared to solid
308 cancers (86% *versus* 43%, respectively ($p=0.04$, Figure 1G, Table S1) and in advanced
309 disease ($p=0.011$) in FR1_TR cohort (Figure 1H, Table S1) but less so, in the CA cohort.
310 Importantly, the LVS phenotype was associated with COVID-19 severity, notably an
311 increased risk to develop a moderate form (defined by thoracic CT scan, hospitalization and
312 oxygen requirement < 9 L/min) in Cancer_FR1_TR ($p=0.032$) (Figure 1I). This trend was
313 confirmed in a third series of French patients from the clinical routine (CR) managed outside
314 the translational ancillary study at Gustave Roussy (called henceforth "Cancer_FR1_CR";
315 Table S1, Figure S3), where 20% cancer patients were diagnosed with LVS and exhibited

316 more severe COVID-19 infections (Figure 1I, $p=0.011$). Again, the hospitalization rates and
317 transfer to intensive care units were increased in LVS compared with SVS patients in
318 Cancer_FR1_TR ($p=0.0018$, Table S1) and Cancer_FR2, respectively ($p=0.02$, Table S1).
319 Finally, the FR2 and Canadian series of LVS cancer patients also tended to exhibit more
320 severe manifestations of COVID-19 compared with SVS Canadian cancer patients (Figure 1I,
321 bottom).

322

323 Of note, the duration of viral RNA shedding correlated with "viral load", *i.e* Ct values
324 at diagnosis, in that cancer patients with LVS experienced lower Ct values at diagnosis than
325 SVS cancer patients in most cohorts for which the data were available (Figure 1J).
326 Importantly, cancer patients doomed to develop LVS presented with lower Ct values at
327 diagnosis than those prone to become SVS in Cancer_FR1 and Cancer_FR2 cohorts (Figure
328 1K). The dynamic course of the infection was significantly different in SVS and LVS, as
329 indicated by the Ct values that remained high for a prolonged period of time in LVS patients
330 compared with SVS (Figure 1L). Of note, Ct values at disease onset were significantly
331 anticorrelated with duration of viral RNA shedding in cancer patients using either N or
332 *Orf1ab/RdRP* gene-specific probe sets.

333 The redundancy analysis (RDA) is an extension of the principal component analysis
334 (PCA) aimed at identifying viral components which depend on other known covariates such
335 as clinical parameters. RDA revealed that, within 30 days from diagnosis, 18% of the
336 variance of the biological parameters are explained by 10 components adjusted for the major
337 clinical parameters for COVID-19 in Cancer_FR1_TR (Figure 1M). These components were
338 mainly influenced by the virus shedding (SVS *versus* COVID-19 negative, $p=0.037$; LVS
339 *versus* COVID-19 negative, $p=0.0010$), COVID severity (mild *versus* COVID-19 negative,
340 $p=0.0030$; moderate *versus* COVID-19 negative, $p=0.0574$; severe *versus* COVID-19
341 negative, p not computable), age ($p=0.0514$), hematological rather than solid malignancy
342 (hematological *versus* solid, $p=0.001$), metastatic status ($p=0.0059$), and Ct values at
343 diagnosis (> 25 *versus* < 25 , $p=0.0738$). As outlined in Table S1, LVS patients tended to be
344 older (66 *versus* 56 years old, $p=0.08$), more metastatic (72% *versus* 29%, $p=0.01$), and
345 experienced increased hospitalization rates (83% *versus* 23%, $p<0.001$) than SVS cancer
346 patients in the Cancer_FR1_TR cohort.

347

348 **Immunological hallmarks of long-term virus carriers at diagnosis**

349

350 Intrigued by these findings, we addressed the question as to whether and how
351 prolonged viral RNA shedding would impact on Cancer_FR1_TR patients with respect to
352 COVID-19-related immunological alterations previously reported for cancer-free infected
353 individuals (Arunachalam et al., 2020; Chua et al., 2020; Kaneko et al., 2020; Laing et al.,
354 2020; Mathew et al., 2020; Silvin et al., 2020; Takahashi et al., 2020). More than 80
355 phenotypic markers were quantified on circulating leukocytes by means of high dimensional
356 spectral flow cytometry, complemented by multiplex ELISAs to detect serum chemokines,
357 cytokines and growth factors. These parameters were recorded within or after the first 20 days
358 of inclusion in the Cancer_FR1_TR protocol, for 25 COVID-19⁺ cancer patients that were
359 divided into LVS *versus* SVS subgroups, in comparison to 43 COVID-19 negative cancer
360 patients (“controls” or “Cntls”) matched for age, gender, co-morbidities, cancer types and
361 tumor extension (Table S2). Asymptomatic individuals and cancer patients enrolled at the
362 recovery phase of COVID-19 (meaning that they became PCR negative) were analyzed
363 separately. Within the first 20 days from diagnosis, LVS presented increased proportions of
364 monocytes among circulating leukocytes (Figure S4A, left panel), and a parallel drop in
365 CD169⁻HLA-DR⁺ within conventional monocytes (Figure S4A, middle panel) and in non-
366 conventional monocytes (CD16⁺CD14^{low/-}, Figure S3A right panel) compared to SVS,
367 cancer controls, asymptomatic or recovered patients, as reported (Carvelli et al., 2020; Silvin
368 et al., 2020). Polymorphonuclear cells (PMN) tended to increase in LVS, specifically
369 immature CD101^{+/-}CD10^{+/-}CD16⁻ neutrophils, compared with SVS, convalescent and
370 controls (Figure 2A-B, upper and lower panels, Figure S4B).

371

372 Importantly, the most significant phenotypic traits distinguishing LVS from SVS
373 featured among the reported hallmarks of severe COVID-19 in cancer-free subjects
374 (Arunachalam et al., 2020; Chua et al., 2020; Kaneko et al., 2020; Laing et al., 2020; Mathew
375 et al., 2020; Silvin et al., 2020; Takahashi et al., 2020) (Figure 2A). In accordance with the
376 reported defects in germinal center formation in secondary lymphoid organs of severe
377 COVID-19 (Kaneko et al., 2020), LVS cancer patients exhibited increased recirculation of
378 activated CXCR5⁺PD-1^{high}CD4⁺ follicular T helper cells (TFH) expressing ICOS and CD38
379 (Figure 2C, left panel), as well as a marked rise in plasmablasts (defined as CD19^{low}CD27^{hi}

380 CD38^{hi}) at the expense of transitional B (CD24⁺CD38^{hi}CD19⁺) and double negative B cells
381 (IgD⁻CD27⁻CD19⁺) (Figure 2C right panel, Figure S4C, Figure 2D). As indicated in the
382 Volcano plot in Figure 2A, immature PMN and double negative B cells were among the most
383 significant immunological features, positively and negatively predicting LVS, respectively
384 (Figure 2B bottom panel and Figure 2D right panel). LVS coincided with prolonged systemic
385 release of, and exposure to, type 1 IFN above levels measured in SVS, controls and recovered
386 individuals (Figure 2E). Type 1 IFN levels anticorrelated with titers of neutralizing anti-S1
387 RBD antibodies (Figure 2F). This landscape of immune profiling was corroborated by non-
388 supervised hierarchical clustering of innate and cognate immunotypes and serum cytokine
389 concentrations analyzed within 30 days from diagnosis. This method allowed to segregate a
390 small cluster of individuals characterized by low Ct values (< 25), and moderate/severe
391 complications of COVID-19, that included metastatic cancer carriers with LVS or SVS
392 (Figure S5). This cluster was separated from the others by typical signs of viral infection,
393 including abundant circulating CD38⁺HLA-DR⁺CD8⁺T cells, plasmablasts, activated TFH
394 cells and high serum IFN α 2a levels (Figure S5). Likewise, while many inflammatory
395 cytokines, chemokines or alarmins (such as IFN γ , CXCL10, IL-4, IL-6 and calprotectin) were
396 elevated in symptomatic COVID-19 individuals compared with controls, asymptomatic and
397 recovered patients, none of them could predict LVS, except a drop in the IFN γ /IFN α 2a and
398 CCL11/CXCL10 ratios whose significance remains unclear ($p=0.016$ and $p=0.0019$,
399 respectively) (Figure S4D-I). Interestingly, innate and cognate immunotypes performed in
400 convalescent patients and controls segregated at random in the non-supervised hierarchical
401 clustering (Figure S6).

402 Altogether, the high dimensional flow cytometry of blood immune subsets indicated
403 that LVS cancer patients harbored the immunological hallmarks of severe COVID-19 at
404 diagnosis.

405

406 **Virus-associated lymphopenia predicted shorter overall survival in the first and second** 407 **surge of the pandemic**

408

409 Lymphocyte loss is a feature of severe COVID-19 in non-cancer patients (Laing et al.,
410 2020; Mathew et al., 2020). Not surprisingly, blood absolute lymphocyte counts (ALC) at
411 diagnosis anticorrelated with the duration of PCR positivity in Cancer_FR1_TR and

412 Cancer_FR1_CR cohorts (Figure 3A). However, although the ALC before the COVID-19
413 pandemic (blood drawn from December 2019 to mid-March 2020) were already somewhat
414 lower in LVS than in SVS cancer patients, the ALC during the outbreak dramatically dropped
415 in cancer patients doomed to develop LVS (in both Cancer_FR1_TR and Cancer_FR1_CR
416 cohorts), more so than in individuals prone to SVS (Figure 3B, left panel). The extent in ALC
417 reduction was more severe in patients presenting LVS than SVS (Figure 3C). Of note, ALC
418 recovered in both patient groups regardless of the LVS/SVS status, supporting the contention
419 that reduced ALC at COVID-19 diagnosis is induced by the virus rather than by the cancer
420 (Figure 3B, left panel). In accord with the finding that LVS correlates with high viral load at
421 symptom onset (Figure 1J-K), higher viral loads at diagnosis were associated with a
422 pronounced COVID19-associated lymphopenia (Figure 3B, right panel).

423 We next assessed the clinical significance of the interaction between Ct values, ALC
424 and cancer patient survival in 110 cancer patients with COVID-19 (Discovery cohort (first
425 surge of the pandemic) including 84 patients from Cancer_FR1 treated at Gustave Roussy and
426 26 patients from Cancer_FR3 treated at Léon Bérard Cancer Center in Lyon, France) (Figure
427 3D, Table 1). Cox logistic regression analyses and Kaplan Meier survival curves were
428 performed after stratification of the patients according to both, Ct and ALC values at
429 diagnosis. The cut-off for the Ct value was 25 and corresponded to the median of the whole
430 cohort FR1+FR3, which coincided with the threshold at which live virus particles can be
431 isolated in 70% of the cases (Jaafar et al., 2020). The cut-off value for ALC was the median
432 found in patients with high viral load (Ct < 25) at diagnosis ($ALC=800/mm^3$). ALC combined
433 with Ct values predicted cancer-related overall survival in univariate analyses across all
434 cancer stages (local, locally advanced or metastatic) (Figure 3D, Table 1). While patients
435 presenting with $ALC > 800/mm^3$ and low viral load (Ct > 25) exhibited prolonged survival, a
436 dismal prognosis affected 21% of them (23/110) who presented both deep lymphopenia (ALC
437 $< 800/mm^3$) and high viral loads (Ct < 25) at diagnosis (Figure 3D) culminating in 40%
438 deaths at 3 months. All 4 groups were comparable in terms of age, gender, co-morbidities,
439 cancer type or staging (Table 1). Multivariate Cox analysis stratified for the cohort origin and
440 adjusted for age (hazard ratio [95% confidence interval]=1.042 [1.013; 1.072], $p=0.0043$),
441 ECOG performance status (4.547 [1.845; 11.206], $p=0.0001$), gender (1.668 [0.775; 3.588],
442 $p=0.1907$) and metastatic status and hematological malignancies (2.747 [1.090; 6.923],
443 $p=0.0322$) confirmed a continuous decrease of risk with the increase of the Ct value (0.841
444 [0.776; 0.911], $p=0.00002$) and the increase of the ALC (0.282 [0.119; 0.672], $p=0.0043$)

445 (Figure 3E). Of note, treatment retardation could not explain the high mortality of patients
446 presenting with a high viral load and low ALC (Table 1).

447 We confirmed these predictors (ALC < 800 & Ct < 25) of poor survival during the
448 second surge of the pandemic (between May 5th, 2020 to November 25th, 2020) in 116 new
449 COVID-19 cancer patients ("Validation", Cancer_FR1 and Cancer_FR3, Figure 1A). Here
450 again, the subset of patients with ALC < 800 & Ct < 25 (n=38/116, 32.7%) exhibited the most
451 reduced overall survival compared to the other groups with > 40% deaths at 50 days (Figure
452 3F). Of note, the reduced survival rate in the subset of patients defined by ALC < 800 & Ct <
453 25 was not a peculiarity of hematological malignancies (characterized by therapy-induced B
454 cell depletion) since it was also observed in patients with solid neoplasia (Figure S7).

455 In conclusion, it appears that uncontrolled viral infection capable of compromising the
456 number and function of circulating lymphocytes predicts lethal outcome of patients with a
457 malignant disease.

458

459 **Immunological, metabolic and metagenomic parameters associated with virus induced-** 460 **lymphocyte loss**

461

462 Multiple and non-exclusive mechanisms could account for virus-associated lymphopenia
463 (Arunachalam et al., 2020; Campbell et al., 2020; Mathew et al., 2020; Moole and
464 Papireddypalli, 2020; Sheng et al., 2017; Song et al., 2020). To further investigate this
465 deleterious virus-induced lymphocyte loss, we searched for the most robust correlates
466 between ALC and immunological, metabolic or pathogenic cues in the Cancer_FR_TR cohort
467 as well as non-cancer COVID-19 patients that we previously reported (Silvin et al., 2020).

468 Firstly, the Spearman correlation matrix of the main immunological and serum
469 markers monitored at the peak of disease (within the first 20 days of disease onset) indicated
470 close interconnections between lymphocyte proportions and their subsets within leukocytes
471 (Figure 4A). Lymphopenia, which is a prominent feature of COVID-19 and a hallmark of
472 severe infection, distinguished LVS from SVS or asymptomatic individuals (Figure S8A-B),
473 as exemplified for the proportion of B lymphocytes among total CD45⁺ leukocytes after 20
474 days of symptoms. As reported (Mathew et al., 2020), the transitional differentiation of naive
475 into effector/memory T cells co-expressing CD38⁺HLA-DR⁺ among CD8⁺T cells is a
476 hallmark of COVID-19 that persisted in LVS compared to controls and SVS ($p=0.002$ and
477 $p=0.012$) (Figure S7C, right panel). In particular, the most compelling LVS-associated T cell

478 subpopulation that expanded in the context of lymphopenia was the non-naive (non-
479 CD45RA⁺CD27⁺) CD8⁺ T subset expressing an activation/exhaustion phenotype
480 characterized by early and sustained expression of PD-1 (Figure 4B), Eomes, Granzyme B,
481 TCF-1 including the pro-apoptotic marker CD95-L (FasL) (Figure 4C-D left panel). The
482 abundance of these non-naïve exhausted PD-1⁺CD8⁺ Tc1 cells positively correlated with the
483 duration of SARS-CoV-2 specific RT-qPCR positivity (Figure 4B, bottom panel and Figure
484 4D, right panel) and may explain, at least partly, the reduced fitness and half-life of peripheral
485 lymphocytes.

486 Secondly, we performed the serum metabolome determined by untargeted and targeted
487 mass spectrometry-based metabolomics analyzing more than 221 metabolites in 31 cancer
488 patients from Cancer_FR1_TR, as well as in a previously described cohort of 66 cancer-free
489 COVID-19⁺ patients for validation (Silvin et al., 2020). The non-supervised hierarchical
490 clustering of the serum metabolome clearly contrasted LVS from SVS patients (Figure S9).
491 The Volcano plot aimed at identifying significant differences between LVS and SVS patients
492 pointed out the biliary salt metabolic pathway segregating SVS from LVS serum (Figure 5A),
493 previously described to have biological significance for lymphocyte fitness and maintenance
494 (Campbell et al., 2020; Moole and Papireddypalli, 2020; Sheng et al., 2017; Song et al.,
495 2020). Secondary biliary acids (such as the murideoxycholic acid (muri-DOC) (Figure 5B,
496 left panel) and the DOC (Figure 5C)) were decreased in LVS compared with SVS and
497 controls and correlated with lower ALC in cancer patients (Figure 5B, right panels) or severe
498 COVID-19 (Figure 5D). Similarly, two other derivatives of DOC (hyo-DOC, urso-DOC)
499 were decreased in LVS (compared to controls and SVS, Figure S10A-B, left panels) and were
500 associated with lymphocyte loss (Figure S10A and S10B, right panels).

501 Another metabolic pathway pertaining to polyamines with high biological significance for
502 age-related immunosenescence (Alsaleh et al., 2020; Puleston et al., 2014; Zhang et al., 2019)
503 was also strongly associated with the duration of RT-qPCR positivity, ALC and disease
504 severity (Figure 5E-G, Figure S9). In particular, the N1, N8-diacetylspermidine that
505 anticorrelated with ALC (Figure 5F, right panel) increased in the serum of LVS patients (but
506 not SVS, Figure 5F, left panel), in accordance with its marked rise in severe COVID-19 in
507 cancer-free individuals (Figure 5G, left panel) where high levels coincided with the
508 lymphocyte drop (Figure 5G, right panel). Of note, the tryptophane/kynurenine or lactic acid
509 metabolites were not relevant in our study (Figure 5A, Figure S9).

510 Thirdly, endotoxemia was shown to correlate with the cytokine storm during COVID-
511 19 (Arunachalam et al., 2020) and might cause activation-induced lymphocyte cell death.
512 Assuming that the gut permeability could be altered during COVID-19-associated intestinal
513 dysbiosis (Yeoh et al., 2021), we studied the circulating microbial populations associated with
514 whole leukocytes by sequencing blood rDNA using next-generation sequencing of V3-V4
515 variable regions of the 16S rRNA bacterial gene as previously described (Paissé et al., 2016).
516 Although we failed to observe significant quantitative differences in blood bacterial load
517 between SVS (n=14) and LVS (n=15) patients, the linear discriminant analysis effect size
518 indicated significant taxonomic differences in the bacteria family members between the two
519 groups (Figure 6A-B). The DNA from Enterobacteriaceae (mainly composed of *Escherichia*
520 *Shigella* genus) was overrepresented in leukocytes of LVS compared with SVS patients
521 (Figure 6A-B, C left panel). The circulating Enterobacteriaceae-related DNA markedly
522 anticorrelated with CCL22 (a hallmark of SVS, Figure 2A), but was strongly associated with
523 the increase of exhausted CD8⁺ T lymphocytes (Figure 6D-E). There was a trend for an
524 increase in the relative abundance of Micrococcaceae in the blood leukocytes of LVS that was
525 confirmed in cancer patients with dismal prognosis (ALC < 800 & Ct < 25) (Figure 6F-G-H).

526 Overall, we conclude that virus-associated lymphopenia may result for complementary
527 or coordinated orthogonal disorders.

528
529
530

531 **Discussion**

532

533 To interrogate viral-host interactions during the COVID-19 pandemic in cancer
534 patients, we studied 1106 patients, among them 59% were cancer bearers
535 (FR1+FR2+FR3+CA), and 1063 COVID-19 positive (Figure 1A). We used high dimensional
536 flow cytometry to perform deep immune profiling of innate, B and T cells and measurements
537 of 51 soluble markers, with temporal analysis of immune changes during infection in one
538 cohort that was further explored by blood metabolomics and metagenomics. This longitudinal
539 immune analysis was linked to virologic and oncological data (Figure S5-S6). Using this
540 approach, we made several intriguing observations.

541

542 First, 51%, 20% and 26% of cancer patients in FR1_TR, FR1_CR and CA,
543 respectively, still shed SARS-CoV-2 RNA after day 40 from symptoms onset (*versus* 2% in

544 HCW), correlating with high viral loads (Ct values < 25) at diagnosis. Indeed, isolation of
545 replication-competent viral strains between 10 and 20 days after symptom onset has been
546 documented in some persons with severe COVID-19, mostly in immunocompromised cases
547 (Kampen et al., 2020). However, about 90% of their specimens no longer yielded replication-
548 competent viruses after day 15 from symptom onset (Ge et al., 2020; Li et al., 2020).
549 Prolonged shedding of influenza, parainfluenza, rhinovirus, seasonal coronavirus and
550 respiratory syncytial virus has previously been detected in immunosuppressed patients (El
551 Ramahi and Freifeld, 2019; Geis et al., 2013; Lehnert et al., 2016, 2013; Milano et al., 2010).
552 Cancer dissemination, cancer therapies and virus-induced lymphopenia might cause an
553 immunodeficiency that eventually jeopardizes virus clearance. The proposed mechanisms by
554 which lymphopenia occurs in COVID-19 (often shared with cancer dissemination) (Péron et
555 al., 2013) include virus-induced atrophy of secondary lymphoid organs (Buja et al., 2020; Lax
556 et al., 2020; Xu et al., 2020), disappearance of germinal centers (Kaneko et al., 2020), direct
557 pro-apoptotic activity of the virus related to ACE2-dependent or ACE2-independent entry
558 into lymphocytes (Pontelli et al., 2020), T cell demise consecutive to activation and
559 exhaustion (Channappanavar and Perlman, 2017; Park, 2020), senescence (Derosa et al.,
560 2020; Westmeier et al., 2020), and antiproliferative effects of lactic acid (Fischer et al., 2007).
561 However, in our study, we found that lymphocyte loss was correlated with decrease of
562 secondary biliary salts in LVS patients, most likely associated with increased gut permeability
563 that lead to bacterial translocation, as we observed increased circulating DNA for
564 Micrococcaceae and Enterobacteriaceae family members. Moreover, the transformation of
565 spermidine into N1, N8 diacetylspermidine was linked to decreased ALC, in accordance with
566 the role of spermidine in preventing ageing-related loss of lymphocyte fitness (Alsaleh et al.,
567 2020; Puleston et al., 2014; Zhang et al., 2019).

568

569 Second, prolonged viral RNA carriage was associated with signs of immunopathology
570 (exacerbated T cell responses, extrafollicular TFH, and plasmablast recirculation, exhausted
571 PD-1⁺ Tc1 cells, sustained serum type 1 IFN levels), likely maintaining a positive feed-back
572 loop for the expression of the interferon-signaling genes product ACE2 (Ziegler et al., 2020)
573 and pro-inflammatory interactions between airway epithelia and immune cells (Chua et al.,
574 2020).

575

576 Third, prolonged SARS-CoV-2 RNA shedding after day 40 might precede the
577 aggravation of both COVID-19 and malignant disease. Indeed, virus and/or cancer-induced
578 lymphopenia and T cell exhaustion may jointly enfeeble tumor immunosurveillance (Rd et al.,
579 2011). Interestingly, SARS-CoV-2 virus -induced immunopathology was accompanied by
580 increased blood levels of IL-8 (Figure S4G) and VEGF (Takahashi et al., 2020), which are
581 well known pro-angiogenic and pro-tumorigenic growth factors, predicting failure to cancer
582 immunotherapy (Sanmamed et al., 2017). Of note, patients with high initial viral loads or
583 LVS tended to accumulate poor prognosis-related parameters than SVS or patients with
584 higher Ct values in both cohorts (Table 1 & Table S1), being older (66 *versus* 56 years old,
585 $p=0.08$), more metastatic at diagnosis of infection (72% *versus* 29%, $p=0.011$), and increased
586 hospitalization rates (83% *versus* 23%, $p=0.001$). As a result, virus-induced lymphopenia
587 markedly predicted early death of patients, within the first 2-3 months post-COVID-19
588 diagnosis in the first and second surge of the pandemic (in more than 200 patients) and call
589 for caution to administer chemotherapy or steroids at the acute phase of the viral infection that
590 exacerbate immunosuppression.

591

592 These observations call for a careful follow up of cancer patients, in particular those
593 bearing hematological and metastatic malignancies, during the second wave of COVID-19.
594 Given the non-consensual efficacy of vaccines against influenza virus in vulnerable
595 individuals suffering from cancer-, virus- and age-associated lymphopenia (Bitterman et al.,
596 2018; Péron et al., 2013), passive immunization of high affinity neutralizing monoclonal
597 antibodies against SARS-CoV-2 at COVID-19 onset might be envisaged. This could be
598 combined with therapeutic stimulation of lymphopoiesis (for instance with rIL-7, G-CSF,
599 inhibitors of indole amine 2,3 deoxygenase), to achieve an immunological tonus that is
600 compatible with anticancer treatments (Cheng et al., 2020; Francois et al., 2018; Laterre et al.,
601 2020). Clinical trials are underway to evaluate rIL-7 against COVID-19, but may benefit from
602 patients stratification based on Ct values, duration of viral RNA shedding and ALC
603 (NCT04407689; NCT04426201; NCT04379076).

604

605 **Acknowledgments:** We are thankful to the Spectral flow cytometry facility team of Gustave Roussy. We thank
606 the ET-EXTRA team (Biological Resource Center (NF 96-600) and the microbiology team for technical help.
607 We thank Dr Aude Jary for helping to set up the subgenomic RNA analysis. We thank the staff from health and
608 safety of Gustave Roussy Cancer Campus for helping to set up the translational research studies. We are thankful
609 to the Genalyte for their supportive help.

610 **Contributions:** L.D., L.Z., A.M. and F.B. conceived and designed the clinical trial. A-G.G., L.D. and L.Z.
611 conceived and designed the translational research trial. A.G., F-X.D., S.T., C.M., L.A., B.B., A.St., B.G.,
612 M.Mer., F.S., A.M., L.D. included patients in the clinical trial. A-G.G., A.D., F-X.D., M.Pic., M.Maz., A.S.,
613 G.D. carried out all the experiments. A-G.G., A.D., F-X.D., A.S., and G.D. performed all the biological analysis.
614 D.D. performed the non-supervised analysis and gave advices for statistical analyses. L.D. and C.A-C-S.
615 collected and analyzed the clinical data. L.T. and A.F. provided the information from the HCW series. A.E., S.K.
616 and B.R. analyzed and provided the clinical data from the Canadian series. B. L.S., D.R., S.G. and S.C. analyzed
617 and provided the clinical data from the IHU series. G.G. and C.B. analyzed CT scan. E.C. and F.G. performed
618 the RT-qPCR. A-G.G., C. A-C-S. and M.Maz. collected the biological data (ALC and Ct values). C.P. collected
619 the samples. M.Maz., Y.H., E.P., C.F., G.F., C.T., I.L. and J-E. F. prepared the biological samples and provided
620 some help for the experiments. A-G.G., A.D. L.Z, and L.D. interpreted data. performed the viral cultures. M.My.
621 and G.G. performed the dosages of antibodies. F-X.D., C.G-D., S.D., N.N., F.A. and A-G.G performed the
622 metagenomic experiments and analyses. B.L., A.R. and A.D. performed metagenomic analyses of blood
623 microbiota. All the authors advised for the interpretation of the data. O.K. gave advices for the design of the
624 figures. L.Z. and L.D. wrote the manuscript, with all authors contributing to writing and providing feedback.

625 **Funding:** A-G.G. was supported by Fondation pour la Recherche Médicale (FRM). L.D. has received support by
626 the Philanthropia Fondation Gustave Roussy. The Gustave Roussy sponsored clinical study on COVID-19
627 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family,
628 Malakoff Humanis, Agnès b. , Izipizi, Ralph Lauren and Sanofi). L.Z. and G.K. were supported by RHU Torino
629 Lumière (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the Seerave Foundation, the Ligue contre le
630 Cancer (équipe labellisée); Agence Nationale de la Recherche (ANR) – Projets blancs; ANR under the frame of
631 E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC);
632 Cancéropôle Ile-de-France; FRM; a donation by Elior; the European Research Council (ERC); Fondation
633 Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut
634 National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx
635 Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
636 (SOCRATE); CARE network (directed by Prof. Mariette, Kremlin Bicêtre AP-HP), and the SIRIC Cancer
637 Research and Personalized Medicine (CARPEM). G.I. and M.P. were supported by Italian Ministry of Health
638 (grants Ricerca CorrenteLinea 1, 1 ‘Infezioni Emergenti e Riemergenti’, projects COVID-2020-12371675 and
639 COVID-2020-12371817). M.My and G.G. were supported by ANR Flash COVID19 program and ARS-CoV-
640 2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs (PI: G.G.).

641 **The authors declare the following competing interests:** L.Z. and G.K. are cofounders of everImmune, a
642 biotech company devoted to the use of commensal microbes for the treatment of cancers. A.G. and A.M. as part
643 of the Drug Development Department (DITEP) are Principal/sub-Investigator of Clinical Trials for Abbvie,

644 Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex
645 Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene,
646 Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol
647 Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai
648 Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited,
649 Eli Lilly, Exelixis, Forma Therapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark
650 Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De
651 Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin
652 Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kga,
653 Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular
654 Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology
655 Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma,
656 Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi
657 Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth
658 Pharmaceuticals France, Xencor, Y's Therapeutics, Research Grants from Astrazeneca, BMS, Boehringer
659 Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from
660 Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH
661 TherAGuiX, Pfizer, Roche. N.L. reports to be a Speaker at Jazz Pharmaceutical E.D. reports grants and personal
662 fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal
663 fees from MERCK SERONO, grants from BMS, grants from MSD, outside the submitted work. O.K. is a
664 cofounder of Samsara Therapeutics. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb,
665 Boehringer–Ingelheim, Eli Lilly Oncology,β. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre,
666 Pfizer and Takeda, outside the submitted work. J-C. S. was a full time employee of AstraZeneca between
667 September 2017 and December 2019, he reports consultancy: Relay Therapeutics, Gritstone Oncology and
668 shares: Gritstone, AstraZeneca, Daiichi-Sankyo, outside the submitted work. L.A. reports consulting fees
669 compensated to institution for Pfizer, Novartis, Bristol Myer Squibb, Ipsen, Roche, MSD, Astra Zeneca, Merck,
670 Amgen, Astellas, Exelixis, Corvus Pharmaceuticals, Peloton Therapeutics, outside the submitted work. F.S.
671 reports consulting fees from AMGEN, Roche, Chugai, Mylan, Mundi Pharma, Leo Pharma, Pierre Fabre
672 Oncology, Helsinn, MSD, Pfizer, BMS, outside the submitted work.

673 **Data and materials availability:** This study includes no data deposited in external repositories.

674

675 **References**

- 676 Albiges, L., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Stoclin, A.,
677 Merad, M., Griscelli, F., Lacroix, L., Netzer, F., Hueso, T., Balleyguier, C., Ammari,
678 S., Colomba, E., Baciarello, G., Perret, A., Hollebecque, A., Hadoux, J., Michot, J.-
679 M., Chaput, N., Saada, V., Hauchecorne, M., Micol, J.-B., Sun, R., Valteau-Couanet,
680 D., André, F., Scotte, F., Besse, B., Soria, J.-C., Barlesi, F., 2020. Determinants of the
681 outcomes of patients with cancer infected with SARS-CoV-2: results from the
682 Gustave Roussy cohort. *Nature Cancer* 1, 965–975. [https://doi.org/10.1038/s43018-](https://doi.org/10.1038/s43018-020-00120-5)
683 020-00120-5
- 684 Alsaleh, G., Panse, I., Swadling, L., Zhang, H., Richter, F.C., Meyer, A., Lord, J., Barnes, E.,
685 Klenerman, P., Green, C., Simon, A.K., 2020. Autophagy in T cells from aged donors
686 is maintained by spermidine and correlates with function and vaccine responses. *Elife*
687 9. <https://doi.org/10.7554/eLife.57950>
- 688 Amrane, S., Tissot-Dupont, H., Doudier, B., Eldin, C., Hocquart, M., Mailhe, M., Dudouet,
689 P., Ormières, E., Ailhaud, L., Parola, P., Lagier, J.-C., Brouqui, P., Zandotti, C.,
690 Ninove, L., Luciani, L., Boschi, C., La Scola, B., Raoult, D., Million, M., Colson, P.,
691 Gautret, P., 2020. Rapid viral diagnosis and ambulatory management of suspected
692 COVID-19 cases presenting at the infectious diseases referral hospital in Marseille,
693 France, - January 31st to March 1st, 2020: A respiratory virus snapshot. *Travel Med*
694 *Infect Dis* 36, 101632. <https://doi.org/10.1016/j.tmaid.2020.101632>
- 695 Anhê, F.F., Jensen, B.A.H., Varin, T.V., Servant, F., Van Blerk, S., Richard, D., Marceau, S.,
696 Surette, M., Biertho, L., Lelouvier, B., Schertzer, J.D., Tchernof, A., Marette, A.,
697 2020. Type 2 diabetes influences bacterial tissue compartmentalisation in human
698 obesity. *Nature Metabolism* 2, 233–242. <https://doi.org/10.1038/s42255-020-0178-9>
- 699 Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R.A.P.M., Scott, M., Hagan, T., Sigal,
700 N., Feng, Y., Bristow, L., Tsang, O.T.-Y., Wagh, D., Coller, J., Pellegrini, K.L.,
701 Kazmin, D., Alaaeddine, G., Leung, W.S., Chan, J.M.C., Chik, T.S.H., Choi, C.Y.C.,
702 Huerta, C., McCullough, M.P., Lv, H., Anderson, E., Edupuganti, S., Upadhyay, A.A.,
703 Bosinger, S.E., Maecker, H.T., Khatri, P., Roupheal, N., Peiris, M., Pulendran, B.,
704 2020. Systems biological assessment of immunity to mild versus severe COVID-19
705 infection in humans. *Science* 369, 1210–1220.
706 <https://doi.org/10.1126/science.abc6261>
- 707 Assaad, S., Avrillon, V., Fournier, M.-L., Mastroianni, B., Russias, B., Swalduz, A., Cassier,
708 P., Eberst, L., Steineur, M.-P., Kazes, M., Perol, M., Michallet, A.-S., Rey, P., Erena-
709 Penet, A.-S., Morel, A., Brahmi, M., Dufresne, A., Tredan, O., Chvetzoff, G., Fayette,
710 J., de la Fouchardiere, C., Ray-Coquard, I., Bachelot, T., Saintigny, P., Tabutin, M.,
711 Dupré, A., Nicolas-Virelizier, E., Belhabri, A., Roux, P.-E., Fuhrmann, C., Pilleul, F.,
712 Basle, A., Bouhamama, A., Galvez, C., Herr, A.-L., Gautier, J., Chabaud, S., Zrounba,
713 P., Perol, D., Blay, J.-Y., 2020. High mortality rate in cancer patients with symptoms
714 of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. *European*
715 *Journal of Cancer* 135, 251–259. <https://doi.org/10.1016/j.ejca.2020.05.028>
- 716 Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L.,
717 Barbian, K., Judson, S.D., Fischer, E.R., Martens, C., Bowden, T.A., de Wit, E.,
718 Riedo, F.X., Munster, V.J., 2020. Case Study: Prolonged Infectious SARS-CoV-2
719 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. *Cell*
720 183, 1901–1912.e9. <https://doi.org/10.1016/j.cell.2020.10.049>
- 721 Aydillo, T., Gonzalez-Reiche, A.S., Aslam, S., van de Guchte, A., Khan, Z., Obla, A., Dutta,
722 J., van Bakel, H., Aberg, J., García-Sastre, A., Shah, G., Hohl, T., Papanicolaou, G.,
723 Perales, M.-A., Sepkowitz, K., Babady, N.E., Kamboj, M., 2020. Shedding of Viable

- 724 SARS-CoV-2 after Immunosuppressive Therapy for Cancer. *N Engl J Med* 383,
725 2586–2588. <https://doi.org/10.1056/NEJMc2031670>
- 726 Becht, E., McInnes, L., Healy, J., Dutertre, C.-A., Kwok, I.W.H., Ng, L.G., Ginhoux, F.,
727 Newell, E.W., 2019. Dimensionality reduction for visualizing single-cell data using
728 UMAP. *Nature Biotechnology* 37, 38–44. <https://doi.org/10.1038/nbt.4314>
- 729 Bitterman, R., Eliakim Raz, N., Vinograd, I., Trestioreanu, A.Z., Leibovici, L., Paul, M.,
730 2018. Influenza vaccines in immunosuppressed adults with cancer. *Cochrane Database*
731 *of Systematic Reviews*. <https://doi.org/10.1002/14651858.CD008983.pub3>
- 732 Boutin, C.-A., Grandjean-Lapierre, S., Gagnon, S., Labbé, A.-C., Charest, H., Roger, M.,
733 Coullée, F., 2020. Comparison of SARS-CoV-2 detection from combined
734 nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-
735 PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument. *J Clin Virol*
736 132, 104615. <https://doi.org/10.1016/j.jcv.2020.104615>
- 737 Buja, L.M., Wolf, D.A., Zhao, B., Akkanti, B., McDonald, M., Lelenwa, L., Reilly, N.,
738 Ottaviani, G., Elghetany, M.T., Trujillo, D.O., Aisenberg, G.M., Madjid, M., Kar, B.,
739 2020. The emerging spectrum of cardiopulmonary pathology of the coronavirus
740 disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of
741 autopsy findings from other United States cities. *Cardiovasc Pathol* 48, 107233.
742 <https://doi.org/10.1016/j.carpath.2020.107233>
- 743 Campbell, C., McKenney, P.T., Konstantinovskiy, D., Isaeva, O.I., Schizas, M., Verter, J.,
744 Mai, C., Jin, W.-B., Guo, C.-J., Violante, S., Ramos, R.J., Cross, J.R., Kadaveru, K.,
745 Hambor, J., Rudensky, A.Y., 2020. Bacterial metabolism of bile acids promotes
746 generation of peripheral regulatory T cells. *Nature* 581, 475–479.
747 <https://doi.org/10.1038/s41586-020-2193-0>
- 748 Carvelli, J., Demaria, O., Vély, F., Batista, L., Benmansour, N.C., Fares, J., Carpentier, S.,
749 Thibult, M.-L., Morel, A., Remark, R., André, P., Represa, A., Piperoglou, C.,
750 Cordier, P.Y., Dault, E.L., Guervilly, C., Simeone, P., Gannier, M., Morel, Y., Ebbo,
751 M., Schleinitz, N., Vivier, E., 2020. Association of COVID-19 inflammation with
752 activation of the C5a–C5aR1 axis. *Nature* 1–5. [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-2600-6)
753 2600-6
- 754 Channappanavar, R., Perlman, S., 2017. Pathogenic human coronavirus infections: causes and
755 consequences of cytokine storm and immunopathology. *Semin Immunopathol* 39,
756 529–539. <https://doi.org/10.1007/s00281-017-0629-x>
- 757 Cheng, L.-L., Guan, W.-J., Duan, C.-Y., Zhang, N.-F., Lei, C.-L., Hu, Y., Chen, A.-L., Li, S.-
758 Y., Zhuo, C., Deng, X.-L., Cheng, F.-J., Gao, Y., Zhang, J.-H., Xie, J.-X., Peng, Hong,
759 Li, Y.-X., Wu, X.-X., Liu, W., Peng, Hui, Wang, J., Xiao, G.-M., Chen, P.-Y., Wang,
760 C.-Y., Yang, Z.-F., Zhao, J.-C., Zhong, N.-S., 2020. Effect of Recombinant Human
761 Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019
762 (COVID-19) and Lymphopenia: A Randomized Clinical Trial. *JAMA Intern Med*.
763 <https://doi.org/10.1001/jamainternmed.2020.5503>
- 764 Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Qiu, X., Solomon, I.H.,
765 Kuo, H.-H., Boucau, J., Bowman, K., Adhikari, U.D., Winkler, M.L., Mueller, A.A.,
766 Hsu, T.Y.-T., Desjardins, M., Baden, L.R., Chan, B.T., Walker, B.D., Lichterfeld, M.,
767 Brigl, M., Kwon, D.S., Kanjilal, S., Richardson, E.T., Jonsson, A.H., Alter, G.,
768 Barczak, A.K., Hanage, W.P., Yu, X.G., Gaiha, G.D., Seaman, M.S., Cernadas, M.,
769 Li, J.Z., 2020. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised
770 Host. *N Engl J Med*. <https://doi.org/10.1056/NEJMc2031364>
- 771 Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O.,
772 Thürmann, L., Kurth, F., Völker, M.T., Kazmierski, J., Timmermann, B., Twardziok,
773 S., Schneider, S., Machleidt, F., Müller-Redetzky, H., Maier, M., Krannich, A.,

- 774 Schmidt, S., Balzer, F., Liebig, J., Loske, J., Suttorp, N., Eils, J., Ishaque, N., Liebert,
775 U.G., von Kalle, C., Hocke, A., Witzenrath, M., Goffinet, C., Drosten, C., Laudi, S.,
776 Lehmann, I., Conrad, C., Sander, L.-E., Eils, R., 2020. COVID-19 severity correlates
777 with airway epithelium-immune cell interactions identified by single-cell analysis.
778 *Nature Biotechnology* 38, 970–979. <https://doi.org/10.1038/s41587-020-0602-4>
- 779 Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T.,
780 Brünink, S., Schneider, J., Schmidt, M.L., Mulders, D.G., Haagmans, B.L., van der
781 Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, J.-L., Ellis, J.,
782 Zambon, M., Peiris, M., Goossens, H., Reusken, C., Koopmans, M.P., Drosten, C.,
783 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro*
784 *Surveill* 25. <https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045>
- 785 Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q.,
786 Xiong, Y., Xiong, H., Wang, C., Chen, C., Xiong, F., Zhang, Y., Peng, Y., Ge, S.,
787 Zhen, B., Yu, T., Wang, L., Wang, H., Liu, Y., Chen, Y., Mei, J., Gao, X., Li, Zhuyan,
788 Gan, L., He, C., Li, Zhen, Shi, Y., Qi, Y., Yang, J., Tenen, D.G., Chai, L., Mucci,
789 L.A., Santillana, M., Cai, H., 2020. Patients with Cancer Appear More Vulnerable to
790 SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. *Cancer Discov*
791 10, 783–791. <https://doi.org/10.1158/2159-8290.CD-20-0422>
- 792 Danlos, F.-X., Grajeda-Iglesias, C., Durand, S., Sauvat, A., Roumier, M., Cantin, D.,
793 Colomba, E., Rohmer, J., Pommeret, F., Baciarello, G., et al., In Press. Metabolomic
794 analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.
795 *Cell Death & Disease*.
- 796 Derosa, L., Melenotte, C., Griscelli, F., Gachot, B., Marabelle, A., Kroemer, G., Zitvogel, L.,
797 2020. The immuno-oncological challenge of COVID-19. *Nature Cancer* 1, 946–964.
798 <https://doi.org/10.1038/s43018-020-00122-3>
- 799 El Ramahi, R., Freifeld, A., 2019. Epidemiology, Diagnosis, Treatment, and Prevention of
800 Influenza Infection in Oncology Patients. *JOP* 15, 177–184.
801 <https://doi.org/10.1200/JOP.18.00567>
- 802 Elkrief, A., Desilets, A., Papneja, N., Cvetkovic, L., Groleau, C., Lakehal, Y.A., Shbat, L.,
803 Richard, C., Malo, J., Belkaid, W., Cook, E., Doucet, S., Tran, T.H., Jao, K., Daaboul,
804 N., Bhang, E., Loree, J.M., Miller, W.H., Vinh, D.C., Bouganim, N., Batist, G.,
805 Letendre, C., Routy, B., 2020. High mortality among hospital-acquired COVID-19
806 infection in patients with cancer: A multicentre observational cohort study. *European*
807 *Journal of Cancer* 139, 181–187. <https://doi.org/10.1016/j.ejca.2020.08.017>
- 808 Escudié, F., Auer, L., Bernard, M., Mariadassou, M., Cauquil, L., Vidal, K., Maman, S.,
809 Hernandez-Raquet, G., Combes, S., Pascal, G., 2018. FROGS: Find, Rapidly, OTUs
810 with Galaxy Solution. *Bioinformatics* 34, 1287–1294.
811 <https://doi.org/10.1093/bioinformatics/btx791>
- 812 Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried,
813 E., Schwarz, S., Rothe, G., Hoves, S., Renner, K., Timischl, B., Mackensen, A., Kunz-
814 Schughart, L., Andreesen, R., Krause, S.W., Kreutz, M., 2007. Inhibitory effect of
815 tumor cell-derived lactic acid on human T cells. *Blood* 109, 3812–3819.
816 <https://doi.org/10.1182/blood-2006-07-035972>
- 817 Francois, B., Jeannet, R., Daix, T., Walton, A.H., Shotwell, M.S., Unsinger, J., Monneret, G.,
818 Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K.,
819 Sherwood, E.R., Hotchkiss, R.S., 2018. Interleukin-7 restores lymphocytes in septic
820 shock: the IRIS-7 randomized clinical trial. *JCI Insight* 3.
821 <https://doi.org/10.1172/jci.insight.98960>
- 822 Garassino, M.C., Whisenant, J.G., Huang, L.-C., Trama, A., Torri, V., Agustoni, F., Baena, J.,
823 Banna, G., Berardi, R., Bettini, A.C., Bria, E., Brighenti, M., Cadranel, J., De Toma,

- 824 A., Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti,
825 R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., La Verde, N., Liu, S.V.,
826 Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G.,
827 Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L.,
828 Wu, Y.-L., Zai, S., Pancaldi, V., Dingemans, A.-M., Van Meerbeeck, J., Barlesi, F.,
829 Wakelee, H., Peters, S., Horn, L., TERAVOLT investigators, 2020. COVID-19 in
830 patients with thoracic malignancies (TERAVOLT): first results of an international,
831 registry-based, cohort study. *Lancet Oncol* 21, 914–922.
832 [https://doi.org/10.1016/S1470-2045\(20\)30314-4](https://doi.org/10.1016/S1470-2045(20)30314-4)
- 833 Ge, H., Wang, X., Yuan, X., Xiao, G., Wang, C., Deng, T., Yuan, Q., Xiao, X., 2020. The
834 epidemiology and clinical information about COVID-19. *Eur J Clin Microbiol Infect*
835 *Dis* 1–9. <https://doi.org/10.1007/s10096-020-03874-z>
- 836 Geis, S., Prifert, C., Weissbrich, B., Lehnert, N., Egerer, G., Eisenbach, C., Buchholz, U.,
837 Aichinger, E., Dreger, P., Neben, K., Burkhardt, U., Ho, A.D., Kräusslich, H.-G.,
838 Heeg, K., Schnitzler, P., 2013. Molecular characterization of a respiratory syncytial
839 virus outbreak in a hematology unit in Heidelberg, Germany. *J Clin Microbiol* 51,
840 155–162. <https://doi.org/10.1128/JCM.02151-12>
- 841 Helleberg, M., Niemann, C.U., Moestrup, K.S., Kirk, O., Lebech, A.-M., Lane, C., Lundgren,
842 J., 2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily
843 Responsive to Two Courses of Remdesivir Therapy. *J Infect Dis* 222, 1103–1107.
844 <https://doi.org/10.1093/infdis/jiaa446>
- 845 Jaafar, R., Aherfi, S., Wurtz, N., Grimaldier, C., Hoang, V.T., Colson, P., Raoult, D., La
846 Scola, B., 2020. Correlation between 3790 qPCR positives samples and positive cell
847 cultures including 1941 SARS-CoV-2 isolates. *Clin Infect Dis*.
848 <https://doi.org/10.1093/cid/ciaa1491>
- 849 Kampen, J.J.A. van, Vijver, D.A.M.C. van de, Fraaij, P.L.A., Haagmans, B.L., Lamers, M.M.,
850 Okba, N., Akker, J.P.C. van den, Endeman, H., Gommers, D.A.M.P.J., Cornelissen,
851 J.J., Hoek, R.A.S., Eerden, M.M. van der, Hesselink, D.A., Metselaar, H.J., Verbon,
852 A., Steenwinkel, J.E.M. de, Aron, G.I., Gorp, E.C.M. van, Boheemen, S. van,
853 Voermans, J.C., Boucher, C.A.B., Molenkamp, R., Koopmans, M.P.G.,
854 Geurtsvankessel, C., Eijk, A.A. van der, 2020. Shedding of infectious virus in
855 hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key
856 determinants. *medRxiv* 2020.06.08.20125310.
857 <https://doi.org/10.1101/2020.06.08.20125310>
- 858 Kaneko, N., Kuo, H.-H., Boucau, J., Farmer, J.R., Allard-Chamard, H., Mahajan, V.S.,
859 Piechocka-Trocha, A., Lefteri, K., Osborn, M., Bals, J., Bartsch, Y.C., Bonheur, N.,
860 Caradonna, T.M., Chevalier, J., Chowdhury, F., Diefenbach, T.J., Einkauf, K., Fallon,
861 J., Feldman, J., Finn, K.K., Garcia-Broncano, P., Hartana, C.A., Hauser, B.M., Jiang,
862 C., Kaplonek, P., Karpell, M., Koscher, E.C., Lian, X., Liu, H., Liu, J., Ly, N.L.,
863 Mitchell, A.R., Rassadkina, Y., Seiger, K., Sessa, L., Shin, S., Singh, N., Sun, W., Sun,
864 X., Ticheli, H.J., Waring, M.T., Zhu, A.L., Alter, G., Li, J.Z., Lingwood, D., Schmidt,
865 A.G., Lichterfeld, M., Walker, B.D., Yu, X.G., Padera, R.F., Pillai, S., 2020. Loss of
866 Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. *Cell*
867 183, 143–157.e13. <https://doi.org/10.1016/j.cell.2020.08.025>
- 868 Lagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A.,
869 Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., Chabrière, E., Stein, A.,
870 Deharo, J.-C., Fenollar, F., Rolain, J.-M., Obadia, Y., Jacquier, A., La Scola, B.,
871 Brouqui, P., Drancourt, M., Parola, P., Raoult, D., 2020. Outcomes of 3,737 COVID-
872 19 patients treated with hydroxychloroquine/azithromycin and other regimens in

- 873 Marseille, France: A retrospective analysis. *Travel Med Infect Dis* 36, 101791.
874 <https://doi.org/10.1016/j.tmaid.2020.101791>
- 875 Laing, A.G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz,
876 M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I., Kamdar, S., Joseph, M.,
877 Davies, D., Davis, R., Jennings, A., Zlatareva, I., Vantourout, P., Wu, Y., Sofra, V.,
878 Cano, F., Greco, M., Theodoridis, E., Freedman, J., Gee, S., Chan, J.N.E., Ryan, S.,
879 Bugallo-Blanco, E., Peterson, P., Kisand, K., Haljasmägi, L., Chadli, L., Moingeon,
880 P., Martinez, L., Merrick, B., Bisnauthsing, K., Brooks, K., Ibrahim, M.A.A., Mason,
881 J., Lopez Gomez, F., Babalola, K., Abdul-Jawad, S., Cason, J., Mant, C., Seow, J.,
882 Graham, C., Doores, K.J., Di Rosa, F., Edgeworth, J., Shankar-Hari, M., Hayday,
883 A.C., 2020. A dynamic COVID-19 immune signature includes associations with poor
884 prognosis. *Nature Medicine* 26, 1623–1635. [https://doi.org/10.1038/s41591-020-1038-](https://doi.org/10.1038/s41591-020-1038-6)
885 6
- 886 Laterre, P.F., François, B., Collienne, C., Hantson, P., Jeannet, R., Remy, K.E., Hotchkiss,
887 R.S., 2020. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts
888 Among Patients With Severe Coronavirus Disease 2019 (COVID-19). *JAMA Netw*
889 *Open* 3. <https://doi.org/10.1001/jamanetworkopen.2020.16485>
- 890 Lax, S.F., Skok, K., Zechner, P., Kessler, H.H., Kaufmann, N., Koelblinger, C., Vander, K.,
891 Bargfrieder, U., Trauner, M., 2020. Pulmonary Arterial Thrombosis in COVID-19
892 With Fatal Outcome□: Results From a Prospective, Single-Center, Clinicopathologic
893 Case Series. *Ann Intern Med* 173, 350–361. <https://doi.org/10.7326/M20-2566>
- 894 Lehnert, N., Schnitzler, P., Geis, S., Puthenparambil, J., Benz, M.A., Alber, B., Luft, T.,
895 Dreger, P., Eisenbach, C., Kunz, C., Benner, A., Buchholz, U., Aichinger, E., Frank,
896 U., Heeg, K., Ho, A.D., Egerer, G., 2013. Risk factors and containment of respiratory
897 syncytial virus outbreak in a hematology and transplant unit. *Bone Marrow*
898 *Transplantation* 48, 1548–1553. <https://doi.org/10.1038/bmt.2013.94>
- 899 Lehnert, N., Tabatabai, J., Prifert, C., Wedde, M., Puthenparambil, J., Weissbrich, B., Biere,
900 B., Schweiger, B., Egerer, G., Schnitzler, P., 2016. Long-Term Shedding of Influenza
901 Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial
902 Epidemiology in Patients with Hematological Disorders. *PLOS ONE* 11, e0148258.
903 <https://doi.org/10.1371/journal.pone.0148258>
- 904 Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y.,
905 Wong, J.Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J.,
906 Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H.,
907 Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang,
908 Y., Shi, G., Lam, T.T.Y., Wu, J.T., Gao, G.F., Cowling, B.J., Yang, B., Leung, G.M.,
909 Feng, Z., 2020. Early Transmission Dynamics in Wuhan, China, of Novel
910 Coronavirus–Infected Pneumonia. *New England Journal of Medicine* 382, 1199–1207.
911 <https://doi.org/10.1056/NEJMoa2001316>
- 912 Lluch, J., Servant, F., Païssé, S., Valle, C., Valière, S., Kuchly, C., Vilchez, G., Donnadieu,
913 C., Courtney, M., Burcelin, R., Amar, J., Bouchez, O., Lelouvier, B., 2015. The
914 Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic
915 Sequencing Pipeline. *PLOS ONE* 10, e0142334.
916 <https://doi.org/10.1371/journal.pone.0142334>
- 917 Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G.,
918 Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng,
919 J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik,
920 P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza,
921 M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D., 2020. COVID-19 in patients with

- 922 lung cancer. *Annals of Oncology* 31, 1386–1396.
923 <https://doi.org/10.1016/j.annonc.2020.06.007>
- 924 Martín-Moro, F., Marquet, J., Piris, M., Michael, B.M., Sáez, A.J., Corona, M., Jiménez, C.,
925 Astibia, B., García, I., Rodríguez, E., García-Hoz, C., Fortún-Abete, J., Herrera, P.,
926 López-Jiménez, J., 2020. Survival study of hospitalised patients with concurrent
927 COVID-19 and haematological malignancies. *British Journal of Haematology* 190,
928 e16–e20. <https://doi.org/10.1111/bjh.16801>
- 929 Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alanio, C.,
930 Kuri-Cervantes, L., Pampena, M.B., D’Andrea, K., Manne, S., Chen, Z., Huang, Y.J.,
931 Reilly, J.P., Weisman, A.R., Ittner, C.A.G., Kuthuru, O., Dougherty, J., Nzingha, K.,
932 Han, N., Kim, J., Pattekar, A., Goodwin, E.C., Anderson, E.M., Weirick, M.E.,
933 Gouma, S., Arevalo, C.P., Bolton, M.J., Chen, F., Lacey, S.F., Ramage, H., Cherry, S.,
934 Hensley, S.E., Apostolidis, S.A., Huang, A.C., Vella, L.A., Unit†, T.Up.C.P., Betts,
935 M.R., Meyer, N.J., Wherry, E.J., 2020. Deep immune profiling of COVID-19 patients
936 reveals distinct immunotypes with therapeutic implications. *Science* 369.
937 <https://doi.org/10.1126/science.abc8511>
- 938 Milano, F., Campbell, A.P., Guthrie, K.A., Kuypers, J., Englund, J.A., Corey, L., Boeckh, M.,
939 2010. Human rhinovirus and coronavirus detection among allogeneic hematopoietic
940 stem cell transplantation recipients. *Blood* 115, 2088–2094.
941 <https://doi.org/10.1182/blood-2009-09-244152>
- 942 Moole, P.K.R., Papireddypalli, J.M.R., 2020. Effect of Deoxycholic Acid on Immune Cells -
943 An Immunophenotyping Analysis of Peripheral Blood and Splenic Lymphocytes in
944 CD57 Female Mice. *International Journal of Pharmaceutical Investigation* 10, 548–
945 552. <https://doi.org/10.5530/ijpi.2020.4.95>
- 946 NCT04407689, n.d. A Multicenter, Randomized, Double-blinded Placebo-controlled Study of
947 Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized
948 Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium
949 (Clinical trial registration No. NCT04407689). clinicaltrials.gov.
- 950 NCT04426201, n.d. A Multicenter, Randomized, Double-blinded Placebo-controlled Study of
951 Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized
952 Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort
953 (Clinical trial registration No. NCT04426201). clinicaltrials.gov.
- 954 Païssé, S., Valle, C., Servant, F., Courtney, M., Burcelin, R., Amar, J., Lelouvier, B., 2016.
955 Comprehensive description of blood microbiome from healthy donors assessed by 16S
956 targeted metagenomic sequencing. *Transfusion* 56, 1138–1147.
957 <https://doi.org/10.1111/trf.13477>
- 958 Park, M.D., 2020. Macrophages: a Trojan horse in COVID-19? *Nature Reviews Immunology*
959 20, 351–351. <https://doi.org/10.1038/s41577-020-0317-2>
- 960 Passamonti, F., Cattaneo, C., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Angelucci, E.,
961 Krampera, M., Cairoli, R., Della Porta, M.G., Fracchiolla, N., Ladetto, M.,
962 Gambacorti Passerini, C., Salvini, M., Marchetti, M., Lemoli, R., Molteni, A., Busca,
963 A., Cuneo, A., Romano, A., Giuliani, N., Galimberti, S., Corso, A., Morotti, A.,
964 Falini, B., Billio, A., Gherlinzoni, F., Visani, G., Tisi, M.C., Tafuri, A., Tosi, P.,
965 Lanza, F., Massaia, M., Turrini, M., Ferrara, F., Gurrieri, C., Vallisa, D., Martelli, M.,
966 Derenzini, E., Guarini, A., Conconi, A., Cuccaro, A., Cudillo, L., Russo, D.,
967 Ciambelli, F., Scattolin, A.M., Luppi, M., Selleri, C., Ortu La Barbera, E., Ferrandina,
968 C., Di Renzo, N., Olivieri, A., Bocchia, M., Gentile, M., Marchesi, F., Musto, P.,
969 Federici, A.B., Candoni, A., Venditti, A., Fava, C., Pinto, A., Galieni, P., Rigacci, L.,
970 Armiento, D., Pane, F., Oberti, M., Zappasodi, P., Visco, C., Franchi, M., Grossi,
971 P.A., Bertù, L., Corrao, G., Pagano, L., Corradini, P., 2020. Clinical characteristics

- 972 and risk factors associated with COVID-19 severity in patients with haematological
973 malignancies in Italy: a retrospective, multicentre, cohort study. *The Lancet*
974 *Haematology* 7, e737–e745. [https://doi.org/10.1016/S2352-3026\(20\)30251-9](https://doi.org/10.1016/S2352-3026(20)30251-9)
- 975 Péron, J., Cropet, C., Tredan, O., Bachelot, T., Ray-Coquard, I., Clapisson, G., Chabaud, S.,
976 Philip, I., Borg, C., Cassier, P., Labidi Galy, I., Sebban, C., Perol, D., Biron, P., Caux,
977 C., Menetrier-Caux, C., Blay, J.-Y., 2013. CD4 lymphopenia to identify end-of-life
978 metastatic cancer patients. *European Journal of Cancer* 49, 1080–1089.
979 <https://doi.org/10.1016/j.ejca.2012.11.003>
- 980 Pontelli, M.C., Castro, I.A., Martins, R.B., Veras, F.P., Serra, L.L., Nascimento, D.C.,
981 Cardoso, R.S., Rosales, R., Lima, T.M., Souza, J.P., Caetité, D.B., Lima, M.H.F. de,
982 Kawahisa, J.T., Giannini, M.C., Bonjorno, L.P., Lopes, M.I.F., Batah, S.S., Siyuan, L.,
983 Assad, R.L., Almeida, S.C.L., Oliveira, F.R., Benatti, M.N., Pontes, L.L.F., Santana,
984 R.C., Vilar, F.C., Martins, M.A., Cunha, T.M., Calado, R.T., Alves-Filho, J.C.,
985 Zamboni, D.S., Fabro, A., Louzada-Junior, P., Oliveira, R.D.R., Cunha, F.Q., Arruda,
986 E., 2020. Infection of human lymphomononuclear cells by SARS-CoV-2. *bioRxiv*
987 2020.07.28.225912. <https://doi.org/10.1101/2020.07.28.225912>
- 988 Puleston, D.J., Zhang, H., Powell, T.J., Lipina, E., Sims, S., Panse, I., Watson, A.S.,
989 Cerundolo, V., Townsend, A.R., Klenerman, P., Simon, A.K., 2014. Autophagy is a
990 critical regulator of memory CD8(+) T cell formation. *Elife* 3.
991 <https://doi.org/10.7554/eLife.03706>
- 992 Q, W., Q, C., H, Z., B, Y., X, H., Y, Z., X, Y., Milk, C., C, X., 2020. Clinical outcomes of
993 coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to
994 immune checkpoint inhibitors. *Cancer Commun (Lond)* 40, 374–379.
995 <https://doi.org/10.1002/cac2.12077>
- 996 Rd, S., Lj, O., Mj, S., 2011. Cancer immunoediting: integrating immunity's roles in cancer
997 suppression and promotion [WWW Document]. *Science (New York, N.Y.)*.
998 <https://doi.org/10.1126/science.1203486>
- 999 Robilotti, E.V., Babady, N.E., Mead, P.A., Rolling, T., Perez-Johnston, R., Bernardes, M.,
1000 Bogler, Y., Caldararo, M., Figueroa, C.J., Glickman, M.S., Joanow, A., Kaltsas, A.,
1001 Lee, Y.J., Lucca, A., Mariano, A., Morjaria, S., Nawar, T., Papanicolaou, G.A.,
1002 Predmore, J., Redelman-Sidi, G., Schmidt, E., Seo, S.K., Sepkowitz, K., Shah, M.K.,
1003 Wolchok, J.D., Hohl, T.M., Taur, Y., Kamboj, M., 2020. Determinants of COVID-19
1004 disease severity in patients with cancer. *Nat Med* 26, 1218–1223.
1005 <https://doi.org/10.1038/s41591-020-0979-0>
- 1006 Ruge, M., Zorzi, M., Guzzinati, S., 2020. SARS-CoV-2 infection in the Italian Veneto
1007 region: adverse outcomes in patients with cancer. *Nature Cancer* 1, 784–788.
1008 <https://doi.org/10.1038/s43018-020-0104-9>
- 1009 Sanmamed, M.F., Perez-Gracia, J.L., Schalper, K.A., Fusco, J.P., Gonzalez, A., Rodriguez-
1010 Ruiz, M.E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., Andueza, M.P.,
1011 Gurrpide, A., Morgado, M., Wang, J., Bacchiocchi, A., Halaban, R., Kluger, H., Chen,
1012 L., Sznol, M., Melero, I., 2017. Changes in serum interleukin-8 (IL-8) levels reflect
1013 and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung
1014 cancer patients. *Annals of Oncology* 28, 1988–1995.
1015 <https://doi.org/10.1093/annonc/mdx190>
- 1016 Schierwagen, R., Alvarez-Silva, C., Servant, F., Trebicka, J., Lelouvier, B., Arumugam, M.,
1017 2020. Trust is good, control is better: technical considerations in blood microbiome
1018 analysis. *Gut* 69, 1362–1363. <https://doi.org/10.1136/gutjnl-2019-319123>
- 1019 Sheng, L., Jena, P.K., Hu, Y., Liu, H.-X., Nagar, N., Kalanetra, K.M., French, Samuel
1020 William, French, Samuel Wheeler, Mills, D.A., Wan, Y.-J.Y., 2017. Hepatic

- 1021 inflammation caused by dysregulated bile acid synthesis is reversible by butyrate
1022 supplementation. *J Pathol* 243, 431–441. <https://doi.org/10.1002/path.4983>
- 1023 Shlomai, A., Ben-Zvi, H., Glusman Bendersky, A., Shafran, N., Goldberg, E., Sklan, E.H.,
1024 2020. Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted
1025 COVID-19 patients. *Critical Care* 24, 539. [https://doi.org/10.1186/s13054-020-03244-](https://doi.org/10.1186/s13054-020-03244-3)
1026 3
- 1027 Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almiere, C.,
1028 Hénon, C., Kosmider, O., Droin, N., Rameau, P., Catelain, C., Alfaro, A., Dussiau, C.,
1029 Friedrich, C., Sourdeau, E., Marin, N., Szwebel, T.-A., Cantin, D., Mouthon, L.,
1030 Borderie, D., Deloger, M., Bredel, D., Mouraud, S., Drubay, D., Andrieu, M.,
1031 Lhonneur, A.-S., Saada, V., Stoclin, A., Willekens, C., Pommeret, F., Griscelli, F., Ng,
1032 L.G., Zhang, Z., Bost, P., Amit, I., Barlesi, F., Marabelle, A., Pène, F., Gachot, B.,
1033 André, F., Zitvogel, L., Ginhoux, F., Fontenay, M., Solary, E., 2020. Elevated
1034 Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild
1035 COVID-19. *Cell* 182, 1401-1418.e18. <https://doi.org/10.1016/j.cell.2020.08.002>
- 1036 Song, X., Sun, X., Oh, S.F., Wu, M., Zhang, Y., Zheng, W., Geva-Zatorsky, N., Jupp, R.,
1037 Mathis, D., Benoist, C., Kasper, D.L., 2020. Microbial bile acid metabolites modulate
1038 gut ROR γ + regulatory T cell homeostasis. *Nature* 577, 410–415.
1039 <https://doi.org/10.1038/s41586-019-1865-0>
- 1040 Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claer, L., Quentric, P., Fadlallah, J.,
1041 Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, C.-E., Mayaux, J.,
1042 Beurton, A., Fourati, S., Lacorte, J.-M., Yssel, H., Parizot, C., Dorgham, K.,
1043 Charneau, P., Amoura, Z., Gorochov, G., 2020. IgA dominates the early neutralizing
1044 antibody response to SARS-CoV-2. *medRxiv* 2020.06.10.20126532.
1045 <https://doi.org/10.1101/2020.06.10.20126532>
- 1046 Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao,
1047 T., Oh, J.E., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Liu, F., Meir, A.,
1048 Sun, J., Wang, E.Y., Casanovas-Massana, A., Wyllie, A.L., Vogels, C.B.F., Earnest,
1049 R., Lapidus, S., Ott, I.M., Moore, A.J., Shaw, A., Fournier, J.B., Odio, C.D.,
1050 Farhadian, S., Cruz, C.D., Grubaugh, N.D., Schulz, W.L., Ring, A.M., Ko, A.I., Omer,
1051 S.B., Iwasaki, A., 2020. Sex differences in immune responses that underlie COVID-19
1052 disease outcomes. *Nature* 1–6. <https://doi.org/10.1038/s41586-020-2700-3>
- 1053 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P.,
1054 Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B.,
1055 Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin,
1056 M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without
1057 Cancer Who Are Hospitalized with COVID-19. *Cancer Cell*.
1058 <https://doi.org/10.1016/j.ccell.2020.09.007>
- 1059 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M.,
1060 Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M.,
1061 Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired
1062 Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. *mBio* 11.
1063 <https://doi.org/10.1128/mBio.02243-20>
- 1064 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A.,
1065 Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T.,
1066 Brünink, S., Schneider, J., Ehmann, R., Zwirgmaier, K., Drosten, C., Wendtner, C.,
1067 2020. Virological assessment of hospitalized patients with COVID-2019. *Nature* 581,
1068 465–469. <https://doi.org/10.1038/s41586-020-2196-x>
- 1069 Xu, X., Chang, X.N., Pan, H.X., Su, H., Huang, B., Yang, M., Luo, D.J., Weng, M.X., Ma,
1070 L., Nie, X., 2020. [Pathological changes of the spleen in ten patients with coronavirus

1071 disease 2019(COVID-19) by postmortem needle autopsy]. *Zhonghua Bing Li Xue Za*
1072 *Zhi* 49, 576–582. <https://doi.org/10.3760/cma.j.cn112151-20200401-00278>

1073 Yeoh, Y.K., Zuo, T., Lui, G.C.-Y., Zhang, F., Liu, Q., Li, A.Y., Chung, A.C., Cheung, C.P.,
1074 Tso, E.Y., Fung, K.S., Chan, V., Ling, L., Joynt, G., Hui, D.S.-C., Chow, K.M., Ng,
1075 S.S.S., Li, T.C.-M., Ng, R.W., Yip, T.C., Wong, G.L.-H., Chan, F.K., Wong, C.K.,
1076 Chan, P.K., Ng, S.C., 2021. Gut microbiota composition reflects disease severity and
1077 dysfunctional immune responses in patients with COVID-19. *Gut*.
1078 <https://doi.org/10.1136/gutjnl-2020-323020>

1079 Zhang, H., Alsaleh, G., Feltham, J., Sun, Y., Napolitano, G., Riffelmacher, T., Charles, P.,
1080 Frau, L., Hublitz, P., Yu, Z., Mohammed, S., Ballabio, A., Balabanov, S., Mellor, J.,
1081 Simon, A.K., 2019. Polyamines Control eIF5A Hypusination, TFE3 Translation, and
1082 Autophagy to Reverse B Cell Senescence. *Mol Cell* 76, 110-125.e9.
1083 <https://doi.org/10.1016/j.molcel.2019.08.005>

1084 Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., Cao,
1085 Y., Yousif, A.S., Bals, J., Hauser, B.M., Feldman, J., Muus, C., Wadsworth, M.H.,
1086 Kazer, S.W., Hughes, T.K., Doran, B., Gatter, G.J., Vukovic, M., Taliaferro, F., Mead,
1087 B.E., Guo, Z., Wang, J.P., Gras, D., Plaisant, M., Ansari, M., Angelidis, I., Adler, H.,
1088 Sucre, J.M.S., Taylor, C.J., Lin, B., Waghray, A., Mitsialis, V., Dwyer, D.F.,
1089 Buchheit, K.M., Boyce, J.A., Barrett, N.A., Laidlaw, T.M., Carroll, S.L., Colonna, L.,
1090 Tkachev, V., Peterson, C.W., Yu, A., Zheng, H.B., Gideon, H.P., Winchell, C.G., Lin,
1091 P.L., Bingle, C.D., Snapper, S.B., Kropski, J.A., Theis, F.J., Schiller, H.B., Zaragosi,
1092 L.-E., Barbry, P., Leslie, A., Kiem, H.-P., Flynn, J.L., Fortune, S.M., Berger, B.,
1093 Finberg, R.W., Kean, L.S., Garber, M., Schmidt, A.G., Lingwood, D., Shalek, A.K.,
1094 Ordovas-Montanes, J., HCA Lung Biological Network. Electronic address: lung-
1095 network@humancellatlas.org, HCA Lung Biological Network, 2020. SARS-CoV-2
1096 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells
1097 and Is Detected in Specific Cell Subsets across Tissues. *Cell* 181, 1016-1035.e19.
1098 <https://doi.org/10.1016/j.cell.2020.04.035>
1099

1100

1101 **Figure Legends**

1102

1103 **Figure 1. Prolonged duration of SARS-CoV-2 RNA shedding correlated with high viral**
1104 **load and COVID-19 severity in patients with cancer.**

1105 **A.** Graphical schema of cohorts and patients' accrual. **B.** Proportion of patients with cancer
1106 from translational research (TR) (Cancer_FR1_TR, n=35, magenta area) or healthcare
1107 workers (HCW, n=45, blue area) by days of RT-qPCR positivity. Vertical dashed line at 40
1108 days represents the 95th percentile of HCW and the median of positivity of patients with
1109 cancer. **C.** Kaplan Meier curves of time to negative RT-qPCR in HCW (n=45, blue dotted
1110 lines) and patients with cancer (Cancer_FR1_TR, n=35, magenta continuous lines). **D.**
1111 COVID-19+ cancer bearing or history of cancer (+) and cancer-free (-) individuals from FR2
1112 treated with hydroxychloroquine +/-azithromycine: number (percentages) of patients with
1113 RT-qPCR positivity beyond 16 days (90th percentile of the cancer-free population of FR2). **E.**
1114 Number (percentages) of HCW, Cancer_FR1 patients (Cancer_FR1_TR) or Canadian patients
1115 with cancer (Cancer_CA) with short, intermediate (grouped in short term viral RNA
1116 shedding, SVS) and prolonged (long term viral RNA shedding, LVS) viral RNA shedding
1117 (**E**), according to the presence/absence of viral symptoms (symptomatic, Sym, *vs*
1118 asymptomatic, Asym) (**F**), diagnosis of hematological (H) versus solid (S) malignancy (**G**),
1119 and cancer staging (localized (L), locally advanced (LA), metastatic (M)) (**H**). **I.** Number
1120 (percentages) of Cancer_FR1 patients (from translational research and clinical routine),
1121 Cancer_FR2 patients (Cancer_FR2) or Canadian patients with cancer (Cancer_CA) divided in
1122 SVS and LVS and regarding their respective COVID-19 severity. **J.** Spearman correlation
1123 between Cycle threshold (Ct) for the RT-qPCR amplification of genes encoding proteins of
1124 SARS-CoV-2 replication-transcription complex at diagnosis and duration of RT-qPCR
1125 positivity for Cancer_FR1 (from translational research and clinical routine), each dot
1126 representing one sample/patient. **K-L.** Ct values for the RT-qPCR amplification of genes
1127 encoding proteins of SARS-CoV-2 replication-transcription complex in nasopharyngeal
1128 swabs performed at diagnosis in SVS *versus* LVS in Cancer_FR1_TR and CR and
1129 Cancer_FR2 (**K**), and dynamics over time from day 0 up to day 80 after inclusion in SVS
1130 (n=33 samples, n=28 patients, orange dots) *versus* LVS (57 samples, n=17 patients, purple
1131 dots) in Cancer_FR1 (from translational research and clinical routine) (**L**). Each line
1132 represents one patient. **M.** Redundancy statistical analysis (RDA) of the cancer and viral
1133 related-clinical factors accounting for the variance of SARS-CoV-2 viral shedding status.
1134 Clinical components were influenced by the virus shedding (SVS *versus* COVID-19 negative,

1135 $p=0.037$; LVS *versus* COVID-19 negative, $p=0.0010$), COVID severity (mild *versus* COVID-
1136 19 negative, $p=0.0030$; moderate *versus* COVID-19 negative, $p=0.0574$; severe *versus*
1137 COVID-19 negative, p not computable), age ($p=0.0514$), hematological rather than solid
1138 malignancy (hematological *versus* solid, $p=0.001$), metastatic status ($p=0.0059$), and Ct
1139 values at diagnosis (≥ 25 *versus* < 25 , $p=0.0738$). Chi-square tests with $*p<0.05$, $**p<0.01$,
1140 $***p<0.001$, $****p<0.0001$.

1141

1142 **Figure 2. Immunotypes associated with prolonged viral RNA shedding in patients with**
1143 **cancer.**

1144 **A.** Volcano plot of the differential cellular and soluble immune parameters contrasting short
1145 term viral RNA shedding (SVS) *versus* long term viral RNA shedding (LVS) during the first
1146 20 days of symptoms. Volcano plot was generated computing for each immune factor: i) the
1147 log₂ of fold change among the mean relative percentages after normalization in SVS *versus*
1148 LVS (x axis); ii) the log₁₀ of p values deriving from Wilcoxon test calculated on relative
1149 percentages in absolute values (y axis). Black and red dots are considered non-significant
1150 ($p<0.05$) or significant ($p>0.05$), respectively. **B-F.** Temporal changes and correlation of
1151 blood leukocyte parameters measured by high dimensional spectral flow cytometry (**B-D**) and
1152 soluble factors IFN α 2a and anti-SARS-CoV-2 IgG (**E, F**) in various phases of COVID-19
1153 presentation (no virus infection (CtIs, grey dots), asymptomatic viral infection (Asym, light
1154 blue dots), symptomatic viral infection examined in the first 20 days ($\leq 20d$) or after 20 days
1155 ($>20d$) of symptoms with those experiencing Short term Viral RNA Shedding (SVS, orange
1156 dots) or Long term Viral RNA Shedding (LVS, purple dots) and RT-qPCR negative COVID-
1157 19 patients in the convalescent phase (Recovery, green dots or circled dots) (supplementary
1158 material, Figure 1). Box plots display a group of numerical data through their 3rd and 1st
1159 quartiles (box), mean (central band), minimum and maximum (whiskers). Each dot represents
1160 one sample, each patient being drawn 1-3 times. Statistical analyses used one-way ANOVA
1161 with Kenward-Roger method to take into account the number of specimen/patient: $*p<0.05$,
1162 $**p<0.01$, $***p<0.001$, $****p<0.0001$. **B-D.** Percentages of neutrophils that do not express
1163 either CD101 and/or CD10 and lost CD16 within the gate of CD45⁺CD56⁻CD3⁻CD19⁻CD15⁺
1164 cells (**B, upper panel**). Spearman correlation between the percentage of immature neutrophils
1165 (CD10^{+/-}CD101^{+/-}CD16⁻) measured within the first 20 days of symptoms with the duration of
1166 SARS-CoV-2 RT-qPCR positivity (**B, lower panel**). **C-D.** Percentages of CD38⁺ICOS⁺
1167 among CXCR5⁺PD-1⁺ non-naive CD4⁺ (**C, left panel**), plasmablasts defined as
1168 CD19^{low}CD38^{high}CD27⁺ within the CD19⁺ gate (**C, right panel**), double negative IgD⁻CD27⁻

1169 among CD19⁺ cells (**D, left panel**) and their Spearman correlation when measured within the
1170 first 20 days of symptoms with the duration of SARS-CoV-2 RT-qPCR positivity (**D, right**
1171 **panel**). **E.** Ultrasensitive electrochemiluminescence assay to monitor the serum
1172 concentrations of IFN α 2a (**E, left panel**) in a kinetic fashion (**E, right panel**). Each line and
1173 dot represent one patient and one sample, respectively and dashed line represents the median
1174 value of controls. **F.** Spearman correlation between the serum IFN α 2a values measured in
1175 symptomatic patients with IgG titers against SARS-CoV-2 S1-RBD considered as continuous
1176 variables (**F, left panel**). The raw data are represented in the **right panel** at both time points
1177 for each group of patients.

1178

1179 **Figure 3. Lymphopenia and high viral load are dismal prognosis factors for overall**
1180 **survival in cancer patients in the first and second surge of the pandemic.**

1181 **A.** Spearman correlation between the absolute lymphocyte counts (ALC) of Cancer_FR1
1182 (from translational research and clinical routine), with the duration of SARS-CoV-2 RT-
1183 qPCR positivity (only evaluable patients for both factors, n=69 patients). **B-C.** ALC of
1184 Cancer_FR1 (from translational research and clinical routine) in SVS (n=37 patients) *versus*
1185 LVS (n=22 patients) subsets (**B, left panel**) or SARS-CoV-2-cycle threshold (Ct) > 25 (n=21
1186 patients) *versus* Ct < 25 (n=29 patients) (**B, right panel**) monitored during the COVID-19
1187 pandemic (“PER”, between -4 and +7 days of the disease diagnosis by RT-qPCR), between
1188 210 and 12 days before the symptom onset of COVID-19 (“PRE”) or within the recovery
1189 period (between 0 and 123 days after negative RT-qPCR) (“POST”) at Gustave Roussy, with
1190 calculation of the reduction between “PRE” and during COVID-19 (**C**). One patient defined
1191 as outlier (at 215%) by ROUT method was excluded from the LVS group for the analysis.
1192 Each line and dot represents one patient and one sample. Statistical analyses used one-way
1193 ANOVA (paired and unpaired) with Kenward-Roger method taking into account the number
1194 of specimen/patient (B): * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.000$ and Mann-Whitney
1195 (C): ** $p < 0.01$. **D.** Kaplan Meier curve and Cox regression analysis of overall survival of
1196 cancer patients from the Discovery (1st surge) cohort (Cancer_FR1+Cancer_FR3), all stages
1197 included, according to ALC and Ct value at diagnosis. Refer to Table 1 for patient
1198 characteristics. **E.** Multivariate Cox regression analysis stratified for the cohort and adjusted
1199 for age, ECOG status, gender and metastatic and/or hematological status of cancer patients
1200 from the Discovery (1st surge) cohort (Cancer_FR1+Cancer_FR3). **F.** Kaplan Meier curve
1201 and Cox regression analysis of overall survival of cancer patients from Validation (2nd surge)

1202 cohort (Cancer_FR1+Cancer_FR3), all stages included, according to ALC and Ct value at
1203 diagnosis. Refer to Table 1 for patient characteristics.

1204

1205 **Figure 4. Prolonged viral shedding is associated with T cell exhaustion.**

1206 **A.** Spearman correlation matrix focusing on the most significant immune variables and serum
1207 analytes monitored within the first 20 days of symptoms in patients diagnosed with COVID-
1208 19 in the Cancer_FR1_TR cohort. Stars indicate significant values ($p<0.05$) for positive (red)
1209 or negative (blue) correlations. **B.** Percentages of PD-1 expressing cells within the non-naïve
1210 CD8⁺CD3⁺ population (**B, upper panel**), monitoring in various phases of COVID-19
1211 presentation (no virus infection (Ctrls, grey dots), asymptomatic viral infection (Asym, light
1212 blue dots), symptomatic viral infection examined in the first 20 days ($\leq 20d$) or after 20 days
1213 ($>20d$) of symptoms with those experiencing Short term Viral RNA Shedding (SVS, orange
1214 dots) or Long term Viral RNA Shedding (LVS, purple dots) and RT-qPCR negative COVID-
1215 19 patients in the convalescent phase (Recovery, green dots or circled dots) among
1216 Cancer_FR1_TR (**B, middle panel**) and Spearman correlation with the duration of SARS-
1217 CoV-2 RT-qPCR positivity measured within the first 20 days of symptoms (**B, lower panel**).
1218 **C.** Percentages of subsets co-expressing PD-1 and Granzyme B (**C, left panel**) or Granzyme
1219 B and FasL (**C, right panel**) in non-naïve CD8⁺. **D.** Percentage of PD-1⁺ and Granzyme B⁺
1220 within the non-naïve CD8⁺ expressing Eomes^{high}TCF-1^{high} gate (**D, left panel**) and Spearman
1221 correlation between this ratio measured within the first 20 days of symptoms with the duration
1222 of SARS-CoV-2 RT-qPCR positivity (**D, right panel**). Box plots display a group of
1223 numerical data through their 3rd and 1st quartiles (box), mean (central band), minimum and
1224 maximum (whiskers). Each dot represents one sample, each patient being drawn 1-3 times.
1225 Statistical analyses used one-way ANOVA with Kenward-Roger method to take into account
1226 the number of specimen/patients: * $p<0.05$, ** $p<0.01$, *** $p<0.001$. Each line and dot
1227 represents one patient and one sample, respectively (B, middle panel).

1228

1229 **Figure 5. Lymphopenia and prolonged viral shedding are associated with perturbations**
1230 **of the polyamine and biliary acid pathways.**

1231 **A.** Volcano plot identifying statistically different serum metabolites between patients
1232 experiencing Short term Viral RNA Shedding (SVS) and those experiencing Long term Viral
1233 RNA Shedding (LVS) in Cancer_FR1_TR cohort. Metabolites significantly different between
1234 both groups are in red and annotated ($p<0.05$, FC >0.5). **B.** Levels of murideoxycholic acid
1235 according to the duration of viral shedding in Cancer_FR1_TR (**left panel**) and Spearman

1236 correlation with absolute lymphocyte count (ALC) (**right panel**). The color code corresponds
1237 to the category of cycle threshold (Ct) and ALC at diagnosis. **C-D**. Serum concentrations of
1238 deoxycholic acid according to the duration of viral shedding in Cancer_FR1_TR (**C**) and the
1239 severity of COVID-19 infection in cancer free individuals (**D**). **E**. Waterfall plot of
1240 Spearman's correlation coefficient (r_s) between ALC and 221 metabolites in the serum of
1241 patients diagnosed positive for COVID-19. **F**. N1, N8-diacetylspermidine relative abundance
1242 in controls, SVS and LVS patients in the Cancer_FR1 cohort, that is negatively correlated
1243 with the ALC. The color code corresponds to the category of cycle threshold (Ct) and ALC at
1244 diagnosis. **G**. Levels of N1, N8-diacetylspermidine in non-cancer COVID-19 patients
1245 according the clinical severity compared to COVID19 negative controls (Ctls) ($p < 0.0001$) (**G**,
1246 **left panel**), that are negatively correlated with the absolute lymphocyte count (ALC) (**G**,
1247 **right panel**). Box plots display a group of numerical data through their 3rd and 1st quartiles
1248 (box), mean (central band), minimum and maximum (whiskers). Each dot represents one
1249 sample, each patient being drawn once for cancer free individuals and 1-2 times for cancer
1250 patients. Statistical analyses used one-way ANOVA with Kenward-Roger method to take into
1251 account the number of specimen/patient (B, left panel, C-E, left panel): * $p < 0.05$, ** $p < 0.01$,
1252 non-parametric unpaired Wilcoxon test (Mann-Whitney) for each two-group comparison:
1253 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

1254

1255 **Figure 6. Lymphopenia and prolonged viral shedding are associated with blood**
1256 **recirculation of Enterobacteriaceae and Micrococcaceae DNA.**

1257 **A**. Stacked bar charts showing the relative abundance of bacterial families obtained by 16S
1258 sequencing of the whole blood samples in patients experiencing Short term Viral RNA
1259 Shedding (SVS) and Long-term Viral RNA Shedding (LVS) among Cancer_FR1_TR. Only
1260 the top 15 most abundant bacterial families are represented (the others are in the category
1261 "Other"). **B**. Linear discriminant analysis effect size (LEfSe) analysis displaying linear
1262 discriminant analysis score (LDA) of the blood bacterial taxa differentially recovered from
1263 SVS (orange) versus LVS (purple) patients (* $p < 0.05$ with Mann-Whitney test between the
1264 two groups of patients). **C**. Mean (bar plots, +/- SEM) and individual values (dot plots) of
1265 relative proportions of Enterobacteriaceae (**C, left panel**) and Micrococcaceae (**C, right**
1266 **panel**) family members in SARS-CoV-2 positive and Recovered patients. Significance
1267 between SVS and LVS patients was evaluated using Mann-Whitney test (* $p < 0.05$). **D-E**.
1268 Spearman correlations between the relative proportions of Enterobacteriaceae with paired
1269 concentrations of CCL22 in serum (**D**) and with paired percentages of Granzyme B

1270 (GzB)⁺PD-1⁺ in Eomes^{hi}TCF-1^{hi} non-naïve CD8⁺ measured in blood (**E**). **F**. Idem as in A.
1271 considering segregating the cohort in two groups; ALC > 0.8G/L and/or Ct > 25 patients
1272 versus ALC < 0.8G/L & Ct < 25 patients. **G**. LEfSe analysis displaying LDA score of the
1273 blood bacterial taxa significantly increased in ALC > 0.8G/L and/or Ct > 25 patients (grey)
1274 and ALC < 0.8G/L & Ct < 25 patients (red). The displayed bacterial taxa are significantly
1275 different (**p*<0.05 with Mann–Whitney test) between the two groups of patients. **H**. Idem as
1276 in C segregating the cohort into the same two groups as in F. Significance between ALC >
1277 0.8G/L and/or Ct > 25 patients and ALC < 0.8G/L & Ct < 25 patients was evaluated using the
1278 Mann-Whitney test (**p*<0.05).

1279

1280

1281 **Table**

1282 **Table 1.** Clinical characteristics of Cancer_FR1 and Cancer_FR3 patients from discovery and
1283 validation cohorts presenting cycle threshold below (Ct<25) or above 25 (Ct>25) and with (<
1284 800/mm³) or without (> 800/mm³) lymphopenia at diagnosis (refer to Figure 3D-F).

1285

1286 Abbreviations: BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; CR:
1287 Clinical Routine; Ct: Cycle threshold; DM: Diabetes mellitus; H: Hematological
1288 malignancies; ICU: Intensive Care Unit; n: number; NED: no evidence of disease; no:
1289 number; PD: Progressive disease; PS: Performance Status; S: Solid tumors; SD/PR: Stable
1290 disease/Partial response; TR: Translational Research; *in the 4 weeks before inclusion.

1291 Statistical analyses: ANOVA (Kruskal-Wallis)(#), Chi-Square or Fisher's exact tests.

1292 °unknown for Cancer_FR3_discovery (n=26 patients), calculations with
1293 Cancer_FR1_discovery, n=84.

1294 °*unknown for Cancer_FR3_validation (n=25 patients), calculations with
1295 Cancer_FR1_validation, n=91.

1296

1297

1298

1299

1300 **Materials and methods**

1301

1302 **All cohorts (refer to Supplementary Material, Table 1)**

1303

1304 **Supplementary Material, Table 1.** List of all cohorts analysed in the study.

Cohorts	Hospital, City, country	Reference	Number of included patients (N) and number analysed (n) <u>DISCOVERY First surge:</u> N=473 N=52 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=35), Ct and ALC at diagnosis (n=34), High dimensional immunology (n=88), Multiplex cytokine arrays (n=88), anti-SARS-CoV-2 antibodies (n=87)	EuDRACt ethical number
Cancer_FR1_TR (ONCOVID)	Gustave Roussy, Villejuif, France		<u>VALIDATION Second surge:</u> N=18 N=18 COVID-19 ⁺ Ct and ALC at diagnosis (n=9)	2020-001250-21
Cancer_FR1_CR	Gustave Roussy, Villejuif, France	Nat Cancer. 2020 Sept;1:965-975.	<u>DISCOVERY First surge:</u> N=178 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=46) Ct and ALC at diagnosis (n=50)	MR4911200520
HCW	Gustave Roussy, Villejuif, France		<u>VALIDATION Second surge:</u> N=170 COVID-19 ⁺ Ct and ALC at diagnosis (n=82) N=100 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=45)	MR004
Cancer_FR2 (cases)	IHU Méditerranée Infections, Marseille, France	TMID. 2020. Jul-Aug;36:101791.	N=175 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=99)	2020-021
Non cancer (controls)	IHU Méditerranée Infections, Marseille, France		N=350 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=198) <u>DISCOVERY First surge:</u> N=287 N=63 COVID-19 ⁺ Ct and ALC at diagnosis (n=26) Electronic Clinical files & virology	
Cancer_FR3 (ONCOVID-19)	Centre Léon Bérard, Lyon, France	Eur J Cancer . 2020 Nov; 139: 68–69. Eur J Cancer 2020 Oct;138:225-227. Eur J Cancer . 2020 Aug; 135: 242–250.	<u>VALIDATION Second surge:</u> Ct and ALC at diagnosis (n=25)	ET20-069
Cancer_CA	Multicenter study, community COVID-19 versus nosocomial, Canada	EJC Cancer. 2020; Sept:139, 181–187	N=252 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=66)	MP-02- 2020-8911 and H20-00892

1305

1306

1307 **Cohorts for the duration of viral PCR positivity.**

1308

1309 *1/ Cancer_FRI_Translational Research (TR) (ONCOVID) clinical trial and regulatory*
1310 *approvals for translational research. Principles.* Gustave Roussy Cancer Center sponsored
1311 the "ONCOVID" trial and collaborated with the academic authors on the design of the trial
1312 and on the collection, analysis, and interpretation of the data. Sanofi provided trial drugs. The
1313 trial was conducted in accordance with Good Clinical Practice guidelines and the provisions
1314 of the Declaration of Helsinki. All patients provided written informed consent. Protocol
1315 approval was obtained from an independent ethics committee (ethics protocol number
1316 EudraCT No: 2020-001250-21). The protocol is available with the full text of this article at
1317 <https://clinicaltrials.gov/ct2/show/NCT04341207>. **Patients.** ONCOVID eligible patients were
1318 adults fitted for, or under, or recently treated by chemotherapy and/or immune-checkpoint
1319 blockade for the treatment of solid tumors or hematological malignancies (Refer to Table 1
1320 and Table S1). Patients diagnosed for COVID-19 from April 10th, 2020 to May 4th, 2020 were
1321 included in the Discovery cohort and patients from May 5th, 2020 to November 25th, 2020
1322 were included in the Validation cohort. **Trial design.** Cancer patients were screened for
1323 SARS-CoV-2 virus carriage by nasopharyngeal sampling at every hospital visit. The presence
1324 of SARS-CoV-2 RNA was detected by RT-qPCR assay in a BSL-2 laboratory. Asymptomatic
1325 and symptomatic patients (*i.e* presenting with fever ($t^{\circ}>38^{\circ}\text{C}$) and/or cough and/or shortness
1326 of breath and/or headache and/or fatigue and/or runny nose and/or sore throat,
1327 anosmy/agueusia) with a positive SARS-CoV-2 RT-qPCR test, shifted to the interventional
1328 phase (tailored experimental approach with Hydroxychloroquine and Azithromycin therapy in
1329 symptomatic SARS-CoV-2 positive subjects). Asymptomatic or symptomatic patients with
1330 negative SARS-CoV-2 RT-qPCR test continued their standard of care anti-cancer treatments.
1331 Repeated RT-qPCR for SARS-CoV-2 on nasopharyngeal swabs and blood samples were
1332 performed to monitor the status for SARS-CoV-2 and the immune response, respectively, in
1333 COVID-19 positive and negative patients. The COVID-19 severity was defined based on
1334 oxygen, imaging and hospitalization criteria. Patients with a mild COVID-19 disease had
1335 limited clinical symptoms not requiring scan or hospitalization; patients with a moderate
1336 COVID-19 disease were symptomatic with a dyspnea and radiological findings of pneumonia
1337 on thoracic scan requiring hospitalization and a maximum of 9L/min of oxygen; severe
1338 patients had respiratory distress requiring intensive care and/or more than 9L/min of oxygen.
1339 **Samples for translational research.** Whole blood was used for high dimensional spectral
1340 flow cytometry analyses. Serum samples were used to monitor the concentrations of

1341 cytokines and chemokines release and to titer anti-SARS-CoV-2 IgG, M and A antibodies
1342 (see blood analysis section) (Supplementary Material Figure 1).

1343

1344 ***2/ Health Care Workers (HCW) of Cancer_FR1_TR.***

1345 The part of the research including health care workers was conducted in compliance with
1346 General Data Protection Regulation (GDPR) and the French Data Protection Authority's
1347 recommendation about Data Protection in clinical researches. Gustave Roussy Data
1348 Protection Officer (DPO) has evaluated this project and sent to the principal investigator a
1349 formalized-operational action plan about data protection compliance: patient's information,
1350 security measures, good practices about pseudonymization, etc. All of the DPO's
1351 recommendations has been applied by the research team. Health care workers diagnosed for
1352 COVID-19 between 24th March and 24th April 2020 were included. Results of RT-qPCR,
1353 cycle threshold, age, gender, and number of comorbidities were collected. Data from health
1354 care workers who refused to participate and/or with a cancer were excluded. In agreement
1355 with MR004 in France, we reported the series to the national information science and liberties
1356 commission.

1357

1358 ***3/ Second series of patients with cancer (Cancer_FR2): CASE-CONTROL study.*** All comers
1359 spontaneously presenting at a general hospital for infectious diseases (IHU Méditerranée
1360 Infections, Marseille, FR) (Table S1) from February 27th, 2020 to December 15th, 2020
1361 composed of 996 COVID-19 patients. We performed a case-control study at a 1:2 paired ratio
1362 where the 175 cancer patients (with a currently treated cancer or history of cancer) were
1363 matched with 350 cancer free individuals on age, gender, comorbidities relevant for COVID-
1364 19. Of note, >75% received hydroxychloroquine and >96% received azithromycine (Table
1365 S1) (Amrane et al., 2020; Lagier et al., 2020). This study was approved by the IHU
1366 Méditerranée Infections review board committee (Méditerranée Infection N°: 2020-021).

1367

1368 ***4/ Third series of cancer patients from Canada (Cancer_CA).*** We used 66 individuals from
1369 the clinical cohort previously reported(Elkrief et al., 2020) for whom data were available
1370 (Table S1). This study was conducted across eight Canadian institutions in Quebec and
1371 British Columbia and was approved by the institutional ethics committee at each site (Ethics
1372 number: MP-02- 2020-8911 and H20-00892).

1373

1374 **5/Fifth series of cancer patients, *Cancer_FRI_Clinical Routine (CR)*.** We used the clinical
1375 cohort previously reported(Albiges et al., 2020) (Table S1). In accordance with the French
1376 regulations, there was no requirement for ethical approval to be sought for this observational
1377 study, based on medical files. Patients diagnosed for COVID-19 from March 14th, 2020 to
1378 April 29th, 2020 were included in the Discovery cohort and from April 29th, 20 to November
1379 25th, 2020 in the Validation cohort. This study was also declared to the Gustave Roussy
1380 Cancer Centre's data protection officer and registered on the website of the French Healthcare
1381 Data Institute (declaration number: MR4911200520).

1382

1383 **Cohorts for the ALC and Ct value predictors: first surge and second surge of the**
1384 **pandemic.**

1385 **1/ *Cancer_FRI_Translational Research (TR) (ONCOVID) clinical trial and regulatory***
1386 ***approvals for translational research.*** Among the 52 patients diagnosed for COVID-19 during
1387 the first surge (from April 10th, 2020 to May 4th, 2020), absolute lymphocyte count (ALC) and
1388 cycle threshold (Ct) were available for 34 patients whom were included in this cohort.

1389 Then, among the 18 patients included in ONCOVID during the second surge (from May 5th,
1390 2020 to November 25th, 2020), absolute lymphocyte count (ALC) and cycle threshold (Ct)
1391 were available for 9 patients whom were included in this cohort

1392

1393 **2/ *Cancer patients referred to the clinical routine (Cancer_FRI_CR)*.** In accordance with
1394 the French regulations, there was no requirement for ethical approval to be sought for this
1395 observational study, based on medical files. Among the 178 patients diagnosed for COVID-19
1396 during the first surge (March 14th, 2020 to April 29th, 2020), ALC and Ct were available for
1397 50 patients whom were included in this cohort. Then, among 170 patients with cancer
1398 diagnosed for COVID-19 during the second surge (from May 5th, 2020 to November 25th,
1399 2020), ALC and cycle threshold Ct were available for 82 patients whom were included in this
1400 cohort.

1401

1402 **3/ *Cancer patients referred to the Centre Léon Bérard, Lyon, France (Cancer_FR3)*.** The
1403 PRE-ONCOVID-19 study was approved by the Institutional review board of the Centre Leon
1404 Bérard on March 12th, 2020 (ET20-069). We used a subset of 25 patients included during the
1405 first surge from March 5th, 2020 to May 4th, 2020 with available ALC and Ct values. We used
1406 26 patients included during the second surge from October 1th, 2020 to December 5th, 2020
1407 with available data.

1408

1409 Patients from each cohort were classified using the same criteria.

1410

1411 **RT-qPCR analysis.** SARS-CoV-2 diagnostic testing of clinical nasopharyngeal swabs or
1412 other samples by RT-qPCR was conducted from March 14th, 2020 to March 23th, 2020 at an
1413 outside facility using the Charité protocol. From March 23th, 2020 testing was performed
1414 internally at the Gustave Roussy. The cycle thresholds were collected only for assays
1415 performed at Gustave Roussy. Nasopharyngeal swab samples were collected using flocked
1416 swabs (Sigma Virocult) and placed in viral transport media. SARS-CoV-2 RNA was detected
1417 using one of two available techniques at Gustave Roussy: the GeneFinder COVID-19 Plus
1418 RealAmp kit (ELITech Group) targeting three regions (*RdRp* gene, nucleocapsid and envelope
1419 genes) on the ELITe InGenius (ELITech Group) or the multiplex real-time RT-PCR
1420 diagnostic kit (the Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR Kit) targeting
1421 three regions (*ORF1ab*, nucleocapsid and spike genes) with the following modifications.
1422 Nucleic acids were extracted from specimens using automated Maxwell instruments
1423 following the manufacturer's instructions (Maxwell RSC simplyRNA Blood Kit; AS1380;
1424 Promega). Real-time RT-PCR was performed on the QuantiStudio 5 Dx Real-Time PCR
1425 System (Thermo Fisher Scientific) in a final reaction volume of 20 μ l, including 5 μ l of
1426 extracted nucleic acids according to the manufacturer instruction.
1427 The cut-off value of 25 for the cycle threshold was based on the median calculated on
1428 Cancer_FR1_TR and the mean calculated on Cancer_FR1_TR+CR.

1429 **RT-PCR for subgenomic RNA (sgRNA) for SARS-CoV-2.** We used the protocol
1430 previously described by Wölfel et al. in *Nature*, 2020. Briefly, the oligonucleotide sequence
1431 of the leader specific primer was as follows: sgLeadSARSCoV2-F;
1432 CGATCTCTTGTAGATCTGTTCTC, and the oligonucleotide sequence of the E primer was
1433 as follows: E_Sarbeco_R; ATATTGCAGCAGTACGCACACA. Briefly, 5 μ l of RNA (>21
1434 ng) were used for the sgRNA RT-PCR assay with Superscript III one-step RT-PCR system
1435 with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany) with 400 nM concentration
1436 of each primer. Thermal cycling was set up as described. Finally, RT-PCR products for
1437 sgRNAs were analyzed on agarose gel 2%.

1438 **Evaluation of SARS-CoV-2 RNA shedding.** The duration of viral shedding was defined as
1439 the number of days from the first positive to the first negative RT-qPCR, after longitudinal
1440 monitoring. In order to prevent an overvaluation of this duration, we considered in this

1441 analysis only patients with an interval below 40 days between the last positive RT-qPCR and
1442 the first negative RT-qPCR. Six patients had one negative RT-qPCR followed by positive RT-
1443 qPCR. We extend the duration to the second negative RT-qPCR for 3 patients with a cycle
1444 threshold below 35 for the gene coding replication-transcription complex and within 6 days
1445 after the first negative result.

1446 **Absolute Lymphocyte Count (ALC).** The absolute lymphocyte count was measured for the
1447 clinical routine using the Sysmex XN (Sysmex, Belgium). Values “PRE” were collected
1448 between 210 and 12 days before the symptom onset of COVID-19, values at diagnosis of the
1449 infection were collected between -4 and +7 days of the disease diagnosis by RT-qPCR, values
1450 “POST” were collected at the recovery time or later, meaning between 0 and 123 days after
1451 the first negative RT-qPCR. For the interpretation, the cut-off value for ALC was the median
1452 found in patients with high viral load at diagnosis ($ALC=800/mm^3$). In parallel, we
1453 considered this value as relevant according to the common terminology criteria for adverse
1454 events where grades of lymphopenia were assigned as following: grade 1 $ALC < \text{lower limit}$
1455 of normal to $800/mm^3$, grade 2 $ALC < 800-500/mm^3$, and grade 3 $ALC < 500-200/mm^3$.

1456 **Blood tests. Sampling.** Blood samples were drawn from patients enrolled in ONCOVID at
1457 Gustave Roussy Cancer Campus (Villejuif, France). Whole human peripheral blood was
1458 collected into sterile vacutainer tubes. **Spectral flow cytometry.** One hundred and twenty-one
1459 whole blood samples from 88 patients (Supplementary Material Figure 1) was mixed at a 1:1
1460 ratio with Whole Blood Cell Stabilizer (Cytodelics), incubated at room temperature for 10
1461 min and transferred to $-80^\circ C$ freezer to await analysis. These samples were secondarily
1462 thawed in a water bath set to $+37^\circ C$. Cells were fixed at a ratio 1:1 with Fixation Buffer
1463 (Cytodelics, ratio 1:1) and incubated for 10 min at room temperature. Red blood cells were
1464 lysed by addition of 2 mL of Lysis Buffer (Cytodelics, ratio 1:4) at room temperature for 10
1465 min. White blood cells were washed with 2 mL of Wash Buffer (Cytodelics, ratio 1:5). Cells
1466 were resuspended in 100 μL extra-cellular antibody cocktail and incubated at room
1467 temperature for 15 min, then washed in Flow Cytometry Buffer (PBS containing 2% of fetal
1468 bovine serum and 2 mM EDTA). For intra-cellular labelling, a step of permeabilization was
1469 performed using 200 μL of eBioscience Foxp3 kit (ThermoFischer); cells were then incubated
1470 for 40 min at $+4^\circ C$, washed in Perm Buffer (ThermoFischer) and resuspended in intra-cellular
1471 antibody cocktail. After incubation, cells were washed in Flow Cytometry Buffer and
1472 resuspended to proceed to the acquisition. All antibodies used are listed in Supplemental

1473 Material Table 2. Samples were acquired on CyTEK Aurora flow cytometer (Cytel
1474 Biosciences). **16S rDNA metagenomic profiling.** DNA from blood was isolated and
1475 amplified in a strictly controlled environment at Vaiomer SAS (Labège, France) using a
1476 stringent contamination-aware approach as discussed previously (Anhê et al., 2020; Lluch et
1477 al., 2015; Païssé et al., 2016; Schierwagen et al., 2020). The microbial populations based on
1478 rDNA present in blood were determined using next-generation sequencing of V3-V4 variable
1479 regions of the 16S rRNA bacterial gene as previously described (Lluch et al., 2015). For each
1480 sample, a sequencing library was generated by addition of sequencing adapters. The joint pair
1481 length was set to encompass a 467 base pairs amplicon (using *Escherichia coli* 16S as a
1482 reference) with a 2×300 paired end MiSeq kit V3 (Illumina, San Diego, CA, USA). The
1483 detection of the sequencing fragments was performed using the MiSeq Illumina® technology.
1484 Targeted metagenomic sequences from microbiota were analysed using the bioinformatic
1485 pipeline from the FROGS guideline (Escudié et al., 2018). Briefly, the cleaning was done by
1486 removing amplicons without the two PCR primers (10% of mismatches were authorised),
1487 amplicons with at least one ambiguous nucleotide ('N'), amplicons identified as chimera
1488 (with vsearch v1.9.5), and amplicons with a strong similarity (coverage and identity $\geq 80\%$)
1489 with the phiX (library used as a control for Illumina sequencing runs). Clustering was
1490 produced in two passes of the swarm algorithm v2.1.6. The first pass was a clustering with an
1491 aggregation distance equal to 1. The second pass was a clustering with an aggregation
1492 distance equal to 3. Taxonomic assignment of amplicons into operational taxonomic units
1493 (OTUs) was produced by Blast+ v2.2.30+ with the Silva 134 Parc databank. To assess if the
1494 richness of microbiota was adequately captured by metagenomic sequencing, a rarefaction
1495 analysis was performed. To ensure a low background signal from bacterial contamination of
1496 reagents and consumables, two types of negative controls consisting of molecular grade water
1497 were added in an empty tube separately at the DNA extraction step and at the PCR steps and
1498 amplified and sequenced at the same time as the extracted DNA of the blood samples. The
1499 controls confirm that bacterial contamination was well contained in our pipeline and had a
1500 negligible impact on the taxonomic profiles of the samples of this study as published before
1501 (Anhê et al., 2020; Lluch et al., 2015; Païssé et al., 2016; Schierwagen et al., 2020). One
1502 sample has been excluded of the analyses for aberrant profile.

1503

1504 **Serum tests.** Serums from 120 samples corresponding to 88 patients (Supplementary Material
1505 Figure 1) were collected from whole blood after centrifugation at 600 g for 10 min at room
1506 temperature and transferred to -80°C freezer to await analysis.

1507 ***Multiplex cytokine and chemokine measurements.*** Serum samples were centrifuged for 15
1508 min at 1,000 g, diluted 1:4, then monitored using the Bio-Plex Pro™ Human Chemokine
1509 Panel 40-plex Assay (Bio-rad, ref: 171AK99MR2) according to the manufacturer's
1510 instructions. 40-plex cytokines and chemokines provided are: CCL1, CCL11, CCL13,
1511 CCL15, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26,
1512 CCL27, CCL3, CCL7, CCL8, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13,
1513 CXCL16, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, GM-CSF, IFN- γ , IL-10, IL-16, IL-1 β ,
1514 IL-2, IL-4, IL-6, MIF, TNF- α . Acquisitions and analyses were performed on a Bio-Plex 200
1515 system (Bio-rad) and a Bio-Plex Manager 6.1 Software (Bio-rad), respectively. Soluble
1516 Calprotectin (diluted 1:100) and IFN- α 2a were analyzed using a R-plex Human Calprotectin
1517 Antibody Set (Meso Scale Discovery, ref: F21YB-3) and the ultra-sensitive assay S-plex
1518 Human IFN- α 2a kit (Meso Scale Discovery, ref: K151P3S-1), respectively, following
1519 manufacturer's instructions. Acquisitions and analyses of soluble Calprotectin and IFN- α 2a
1520 were performed on a MESO™ QuickPlex SQ120 reader and the MSD's Discovery
1521 Workbench 4.0. Each serum sample was assayed twice with the average value taken as the
1522 final result.

1523 ***Serology: Anti-SARS-CoV-2 immunoglobulins.*** Serum was collected from whole blood after
1524 centrifugation at 600 g for 10 min at room temperature and transferred to -80°C freezer to
1525 await analysis. Serological analysis SARS-CoV-2 specific IgA, IgM and IgG antibodies were
1526 measured in 119 serum samples from 87 patients (Supplementary Material Figure 1) with The
1527 Maverick™ SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc. USA) according to
1528 the manufacturer's instructions. The Maverick™ SARS-CoV-2 Multi-Antigen Serology
1529 Panel (Genalyte Inc) is designed to detect antibodies to five SARS-CoV-2 antigens:
1530 nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2 and Spike S1 with in a multiplex format
1531 based on photonic ring resonance technology (Sterlin et al., 2020). This system detects and
1532 measure with good reproducibility changes in resonance when antibodies bind to their
1533 respective antigens in the chip. The instrument automates the assay. Briefly, 10 μ l of each
1534 serum samples were added in a sample well plate array containing required diluents and
1535 buffers. The plate and chip are loaded in the instrument. First the chip is equilibrated with the
1536 diluent buffer to get baseline resonance. Serum sample is then charged over the chip to bind
1537 specific antibodies to antigens present on the chip. Next, chip is washed to remove low
1538 affinity binders. Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -
1539 IgM secondary antibodies.

1540 **Metabolomics analysis.** Samples were prepared as previously described (Danlos et al., In
1541 Press). Briefly, serum samples were mixed with ice-cold extraction mixture (methanol/water,
1542 9/1, v/v, with a mixture of internal standards), then centrifugated. Supernatants were collected
1543 for widely-targeted analysis of intracellular metabolites. **GC/MS analysis.** GC-MS/MS
1544 method was performed on a 7890B gas chromatography (Agilent Technologies, Waldbronn,
1545 Germany) coupled to a triple quadrupole 7000C (Agilent Technologies, Waldbronn,
1546 Germany) equipped with a high sensitivity electronic impact source (EI) operating in positive
1547 mode. **Targeted analysis of bile acids.** Targeted analysis was performed on a RRLC 1260
1548 system (Agilent Technologies, Waldbronn, Germany) coupled to a QTRAP 6500+ (Sciex)
1549 equipped with an electrospray source operating in negative mode. Gas temperature was set to
1550 450°C, with ion source gas 1 and 2 set to 30 and 70, respectively. **Targeted analysis of**
1551 **polyamines.** Targeted analysis was performed on a RRLC 1260 system (Agilent
1552 Technologies, Waldbronn, Germany) coupled to a QQQ 6410 (Agilent Technologies)
1553 equipped with an electrospray source operating in positive mode. The gas temperature was set
1554 to 350°C with a gas flow of 12 l/min. The capillary voltage was set to 3.5 kV. **Targeted**
1555 **analysis of SCFA.** Targeted analysis was performed on a RRLC 1260 system (Agilent
1556 Technologies, Waldbronn, Germany) coupled to a QQQ 6410 (Agilent Technologies)
1557 equipped with an electrospray source operating in negative mode. Gas temperature was set to
1558 350°C with a gas flow of 12 L/min. Capillary voltage was set to 4.0 kV. **Pseudo-targeted**
1559 **analysis of intracellular metabolites.** The profiling experiment was performed with a Dionex
1560 Ultimate 3000 UHPLC system (Thermo Scientific) coupled to a Q-Exactive (Thermo
1561 Scientific) equipped with an electrospray source operating in both positive and negative mode
1562 and full scan mode from 100 to 1200 m/z. The Q-Exactive parameters were: sheath gas flow
1563 rate 55 au, auxiliary gas flow rate 15 au, spray voltage 3.3 kV, capillary temperature 300°C,
1564 S-Lens RF level 55 V. The mass spectrometer was calibrated with sodium acetate solution
1565 dedicated to low mass calibration.

1566

1567 **Data analysis. Spectral flow cytometry.** Fcs files were exported and analyzed using FlowJo
1568 software using the gating strategy showed in Supplementary material, Figure 2. Briefly, gates
1569 on CD45⁺, CD3⁺ or CD19⁺ from the myeloid, T cell and B panels, respectively, were
1570 exported in an fcs file. All exported gates from one panel were used to generate an
1571 UMAP(Becht et al., 2019). As shown on Supplementary material Figures 3 and 4, we used
1572 relative expression and manual gating strategy. For patients treated by anti-PD-1 monoclonal
1573 antibody, the gates including PD-1 were excluded of the analysis. For patients treated by anti-

1574 CD38 monoclonal antibody, the gates including CD38 were excluded of the analysis.

1575 **Representation of the results.** Data representation was performed with software R v3.3.3
1576 using tidyverse, dplyr, ggplot2, ggpubr, pheatmap, corrplot or Hmisc packages or GraphPad
1577 Prism 7.

1578

1579 **Statistical analyses.** Calculations and statistical tests were performed either with R v3.3.3 or
1580 Prism 7 (GraphPad, San Diego, CA, USA). Unless stated, p-values are two-sided with 95%
1581 confidence intervals for the reported statistic of interest. Individual data points representing
1582 the measurement from one patient are systematically calculated from the corresponding
1583 distribution. Biological parameters associated to statistically significant differences between
1584 groups were considered for the data visualization described below. Group comparison was
1585 performed using one-way ANOVA with the lmer function of the lme4 R package. The p-
1586 values were computed with the Kenward-Roger method, available in the lmerTest R package.
1587 Spearman correlations were computed using Hmisc and Pheatmap R package. Hierarchical
1588 clustering of the patient's factors was performed using using the hclust R package. The
1589 redundancy analysis (RDA) was performed using the vegan R package to explore the
1590 association between the clinical variables and the biological parameters correlation latent
1591 structure. The RDA performs variance decomposition such as principal component analysis,
1592 but including additional supervised components depending on the explanatory variables (e.g.
1593 clinical factors). The association of the clinical factors with the biological parameter
1594 correlation latent structure was tested using permutation test. Kaplan–Meier methodology was
1595 used to estimate the probability of overall survival as well as to visualize the median time of
1596 SARS-CoV-2 RNA shedding for each group (HCW and Cancer). One-way ANOVA (paired
1597 and unpaired) with Kenward-Roger method was used to calculate p-value between ALC
1598 among groups of viral RNA shedding and Ct values. Chi-Square, Fischer test were used to
1599 calculate the differences in proportion between groups. Comparing two groups, Mann-
1600 Whitney test was used. Univariate analyses were performed with the Cox regression model.
1601 $p < 0.05$ was considered as significant. Multivariate Cox analysis was performed using the
1602 survival R package stratified for the cohort and adjusted for the age, ECOG performance
1603 status, gender and metastatic status and hematological malignancy.

1604

1605

1606 **Supplemental figure legends**

1607

1608 **Figure S1. Cancer_FR1_Translational Research patient clinical characteristics.**

1609 **A.** Consort flow chart diagram of ONCOVID (Cancer_FR1_Translational Research (TR))
1610 patients at trial inclusion, delineating COVID-19 positive cases retained for the evaluation of
1611 duration of SARS-CoV-2 RNA shedding and cycle threshold (Ct) with absolute lymphocyte
1612 count (ALC) at diagnosis, and their controls for the translational research ancillary study
1613 (Cancer_FR1). **B-G.** Number (percentages) of patients with cancer diagnosed with COVID-
1614 19 and with hematological (H) *versus* solid (S) malignancy (**B-C**), presenting symptomatic
1615 (Sym) *vs* asymptomatic (Asym) infection (**D-E**), and at different stages of disease (localized
1616 (L), locally advanced (LA), metastatic (M)) of their cancer (**F-G**).

1617

1618 **Figure S2. Reliability of the monitoring of viral shedding.**

1619 Consort flow chart diagram of patients with cancer (**A**) and healthcare workers (HCW) (**B**)
1620 diagnosed with COVID-19 retained for the evaluation of duration of SARS-CoV-2 RNA
1621 shedding in the ancillary study presented in Figure 1.

1622

1623 **Figure S3. Patient clinical characteristics in a second series of patients with cancer at**
1624 **Gustave Roussy, Cancer_FR1_Clinical Routine.**

1625 **A.** Consort flow chart diagram of second series patients with cancer (Cancer_FR1_Clinical
1626 Routine (CR)) diagnosed with COVID-19 at Gustave Roussy and monitored in clinical
1627 routine during the pandemic (March 14th - April 29th) retained for the evaluation of duration
1628 of SARS-CoV-2 RNA shedding and cycle threshold (Ct) with absolute lymphocyte count
1629 (ALC) at diagnosis. **B-G.** Proportions of COVID-19 cancer patients with hematological (H)
1630 *vs* solid malignancy (S) (**B-C**), presenting symptomatic (Sym) *vs* asymptomatic (Asym)
1631 infection (**D-E**), and at different stages of disease (localized (L), locally advanced (LA),
1632 metastatic (M)) of their cancer (**F-G**).

1633 **Figure S4. Immunotypes associated with prolonged viral RNA shedding in patients with**
1634 **cancer.**

1635 Temporal changes and correlation of blood leukocyte parameters measured by high
1636 dimensional spectral flow cytometry and multiple soluble factors in various phases of
1637 COVID-19 presentation (no virus infection (Ctrls, grey dots), asymptomatic viral infection
1638 (Asym, light blue dots), symptomatic viral infection examined in the first 20 days ($\leq 20d$) or
1639 after 20 days ($>20d$) of symptoms with those experiencing short term viral RNA shedding

1640 (SVS, orange dots) or long term viral RNA shedding (LVS, purple dots) and RT-qPCR
1641 negative COVID-19 patients in the convalescent phase (Recovery, green dots)). Box plots
1642 display a group of numerical data through their 3rd and 1st quartiles (boxe), mean (central
1643 band), minimum and maximum (whiskers). Each dot represents one sample, each patient
1644 being drawn 1-3 times. Statistical analyses used one-way ANOVA with Kenward-Roger
1645 method to take into account the number of specimen/patient: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
1646 **** $p < 0.0001$. **A.** Monocyte subset (**A, left panel**) defined within the $CD45^+CD3^-CD56^-$
1647 $CD19^-CD15^-$ gate, focusing on $CD169^+HLA-DR^+$ in $CD16^{low}CD14^+$ classical monocytes
1648 (cMo) (**A, middle panel**) and $CD16^+CD14^{low}$ non-classical monocytes (non-cMo) (**A, right**
1649 **panel**). **B.** Neutrophil subset (**B, left panel**) defined within the $CD45^+CD15^+$ gate, focusing
1650 on $CD101$, $CD10$ simple positive or double negative subset (**B, right panel**). **C.** Transitional
1651 B cell subset ($CD24^+CD38^{hi}$) in B cells. **D.** Serum titers of anti-S1 RBD IgA (**D, left panel**)
1652 and IgM (**D, right panel**) in various patient groups at different kinetics. **E-I.** Temporal
1653 changes of serum concentrations of various soluble factors and their ratios measured in
1654 various phases of COVID-19 presentation.

1655

1656 **Figure S5. Non-supervised hierarchical clustering of 33 cancer patients negative for**
1657 **COVID-19 and 21 patients with cancer diagnosed positive for COVID-19 investigated**
1658 **for immunophenotyping and viral parameters within the first 30 days from symptoms**
1659 **onset (or positive RT-qPCR for asymptomatic patients) or COVID-19 negative controls.**

1660 The heatmap shows z score-normalized concentration of parameters. Each column represents
1661 a patient and each row a parameter. The color gradient from blue up to red indicates
1662 increasing gradients of concentrations.

1663

1664 **Figure S6. Non supervised hierarchical clustering of 29 cancer patients negative for**
1665 **COVID-19 and 35 patients with cancer recovered from COVID-19 investigated for**
1666 **immunophenotyping and viral parameters.**

1667 The heatmap shows z score-normalized concentration of parameters. Each column represents
1668 a patient and each row a parameter. The color gradient from blue up to red indicates
1669 increasing gradients of concentrations. In order to assess the immune characteristics after
1670 COVID-19 events in convalescent vs controls, we compared only alive patients and we
1671 excluded all the dead ones in this analysis.

1672

1673 **Figure S7. Lymphoid parameters associated with prolonged viral RNA shedding in**
1674 **patients with cancer.**

1675 Temporal changes and correlation of blood leukocyte parameters measured by high
1676 dimensional spectral flow cytometry in various phases of COVID-19 presentation (no virus
1677 infection (Ctls, grey dots), asymptomatic viral infection (Asym, light blue dots), symptomatic
1678 viral infection examined in the first 20 days ($\leq 20d$) or after 20 days ($>20d$) of symptoms with
1679 those experiencing short term viral RNA shedding (SVS, orange dots) or long term viral RNA
1680 shedding (LVS, purple dots) and RT-qPCR negative COVID-19 patients in the convalescent
1681 phase (Recovery, green dots)). Box plots display a group of numerical data through their 3rd
1682 and 1st quartiles (box), mean (central band), minimum and maximum (whiskers). Each dot
1683 represents one sample, each patient being drawn 1-3 times. Statistical analyses used one-way
1684 ANOVA with Kenward-Roger method to take into account the number of specimen/patient:
1685 $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, $****p < 0.0001$. **A.** Lymphocyte relative proportion within
1686 the CD45⁺ gate, encompassing CD3⁺, CD56⁺ and CD19⁺ cell subsets (**A, left panel**) with (**A,**
1687 **middle**) corresponding to CD19⁺ B cells and (**A, right**) corresponding to NK cells such as
1688 CD45⁺CD3⁻CD56⁺CD19⁻. **B.** CD8⁺ T cells (**B, left panel**) or CD4⁺ T cells (**B, right panel**)
1689 within the CD45⁺CD3⁺ gate. **C.** Percentages of EM2 defined as CD45RA⁻CD27⁻CD62L⁺ in
1690 CD8⁺ T cells (**C, left panel**) and subset co-expressing HLA-DR and CD38 in non-naïve CD8⁺
1691 (**C, right panel**).

1692

1693 **Figure S8. Impact of ALC and Ct values in cancer patients survival according to their**
1694 **cancer type (hematological versus solid).**

1695 Kaplan Meier curve and Cox regression analysis of cancer-related overall survival in patients
1696 pooled in the two institutes (Gustave Roussy and Centre Léon Bérard: Cancer_FR1_TR,
1697 Cancer_FR1_CR and Cancer_FR3) and in the two surges of the pandemic to analyze the
1698 impact of the Absolute Lymphocyte Count (ALC) and Cycle threshold (Ct) at diagnosis in
1699 solid tumors only (**A**) (n=177 patients) and hematological tumors only (**B**) (n=49 patients).

1700

1701 **Figure S9. Serum metabolome variations in COVID-19 positive cancer patients,**
1702 **according to viral shedding duration, cycle threshold and absolute lymphocyte counts at**
1703 **diagnosis.**

1704 Targeted metabolomics analysis was performed on serum samples from confirmed COVID-
1705 19 patients, allowing the identification of significant changes in the relative abundance of 221
1706 metabolites, illustrated by a heatmap. Hierarchical clustering (Euclidean distance, ward

1707 linkage method) of the metabolite abundance is shown, with each row representing a
1708 metabolite and each column corresponding to a different patient. Polyamine derived
1709 metabolites, and bile acids and their conjugates are marked in red.

1710

1711 **Figure S10. Lymphopenia and viral shedding are associated with perturbations in**
1712 **polyamine and secondary biliary acid pathways.**

1713 **A-B. Biliary salt pathway related-metabolites.** Mass-spectrometry based abundance of
1714 serum Hyo-(**A**) and Urso-(**B**) deoxycholic acid in LVS (purple dots), SVS (orange dots) (**left**
1715 **panel**) compared to controls (Ctls) and Spearman correlations with ALC (**right panel**), color
1716 code corresponds to status for COVID-19 and the category of viral shedding. **C-D.**
1717 **Polyamine pathway-related metabolites.** N1-acetylspermidine relative abundance
1718 significantly increased in long term viral RNA shedding (LVS, purple dots) regarding
1719 controls (Ctls) (**C, left panel**) and anticorrelated with ALC (**C, right panel**), color code
1720 corresponds to the category of Ct and ALC at diagnosis. N1, N12-diacetylspermine relative
1721 abundance significantly increased in critical non-cancer patients (**D, left panel**) and
1722 anticorrelated with Absolute Lymphocyte Count (ALC) (**D, right panel**). Box plots display a
1723 group of numerical data through their 3rd and 1st quartiles (box), mean (central band),
1724 minimum and maximum (whiskers). Each dot represents one sample, each patient being
1725 drawn 1 time for cancer free individuals and 1-2 times for cancer patients. Statistical analyses
1726 used one-way ANOVA with Kenward-Roger method to take into account the number of
1727 specimen/patient (A-B-C left panel): * $p < 0.05$, ** $p < 0.01$), non-parametric unpaired Wilcoxon
1728 test (Mann-Whitney) for each two-group comparison (D left panel): * $p < 0.05$, ** $p < 0.01$,
1729 *** $p < 0.001$, **** $p < 0.0001$.

1730

1731 **Supplemental tables**

1732

1733 **Table S1.** Clinical and viral characteristics of patients COVID-19⁺ enrolling in ONCOVID.
1734 Clinical and viral characteristics of patients COVID-19⁺ enrolling in three French COVID-19⁺
1735 and one Canadian cohort according to the duration of viral shedding (SVS vs LVS).

1736

1737 **Table S2.** Clinical characteristics of Cancer_FR1 available for translational research

1738

1739 **Supplementary Material, Figures and Tables**

1740

1741 **Supplementary Material, Figure 1.** Strategy of flow cytometry analysis. Briefly, manual
1742 gating was performed to extract fcs files of CD45⁺, CD3⁺ T cells and CD19⁺ B cells using the
1743 myeloid, T cell and B cell panels, respectively. An example of gating strategy was shown on
1744 one sample. Fcs files were compiled in uniform manifold approximation and projection
1745 (UMAP) representation. Concatenation of all the samples was shown on the UMAP
1746 representation. Relative expression of markers was used to gate the population of interest.

1747

1748 **Supplementary Material, Figure 2.** Relative expression of principal markers used to gate
1749 the populations explored with the myeloid panel. An example of gating strategy of
1750 monocytes, as well as CD169 and HLA-DR, was shown in one sample.

1751

1752 **Supplementary Material, Figure 3. A.** Relative expression of principal markers used to gate
1753 the populations explored with the T cell panel (**A, top panel**). An example of gating strategy
1754 of follicular helper T cells and the activated subset was shown on one sample (**A, bottom**
1755 **panel**). **B.** Relative expression of principal markers used to gate the populations explored with
1756 the B cell panel.

1757

1758

1759 **Supplementary Material, Table 2.** List of monoclonal antibodies used for the stainings.

Panel	Fluorochrome	Marker	Manufacturer	Clone	lot number	Target
Myeloid cells/global panel	PE-Cy5	CD10	eBioscience	eBioCB-CALLA	4278756	extra-cellular
	AF6747	CD101	BioLegend	BB27	B221821	extra-cellular
	BV480	CD117	BD	YB5.B8	9186378	extra-cellular
	BV786	CD11b	BD	ICRF44	9294787	extra-cellular
	BV711	CD11c	BD	B-ly6	9169751	extra-cellular
	BV421	CD14	BioLegend	M5E2	B240487	extra-cellular
	BV650	CD141	BD	1A4	9294829	extra-cellular
	Pacific Blue	CD15	BioLegend	W6D3	B210001	extra-cellular
	BUV496	CD16	BD	3G8	7306671	extra-cellular
	PE	CD169	BioLegend	7-239	B279791	extra-cellular
	BUV563	CD19	BD	SJ25C1	9191109	extra-cellular
	BB700	CD3/CD56	BD	SK7/B159	9108776/8319951	extra-cellular
	APC	CD36	BioLegend	5-271	B257710	extra-cellular
	FITC	CD37	BioLegend	B280601	B280601	extra-cellular
	BV605	CD38	BD	HB7	9072931	extra-cellular
	BUV805	CD4	BD	SK3	9136550	extra-cellular
	BUV395	CD45	BD	HI30	9004778	extra-cellular
	PE-Cy7	CD63	BioLegend	H5C6	B257710	extra-cellular
	AF700	CD64	R&D	10.1	1522423	extra-cellular
	BV510	CD8	BD	SK1	9210674	extra-cellular
PE-Dazzle594	CXCR4	BioLegend	12G5	B257889	extra-cellular	
BUV737	FceRI	BD	AER-37	1043538	extra-cellular	
APC-H7	HLA-DR	BD	G46-6	8318843	extra-cellular	
T cell panel	BV650	CD95	BD	DX2	8155876	extra-cellular
	APC-Cy7	Bcl-6	BD	K112-91	50675	intra-cellular
	PE	Blimp1	R&D system	PRDM1	ACTT0219051	intra-cellular
	BB515	CD127	BD	HIL-7R-M21	6320843	extra-cellular
	BV711	CD16	BioLegend	3G8	B256275	extra-cellular
	APC	CD178/CD95-L	BD	NOK-1	9274343	extra-cellular
	BV510	CD185/CXCR5	BD	RF8B2	9102753	extra-cellular
	BUV395	CD19	BD	SJ25C1	7167875	extra-cellular
	PerCp	CD197/CCR7	BioLegend	G043H7	B279387	extra-cellular
	BV785	CD25	BioLegend	BC96	B254092	extra-cellular
	PE-C7	CD27	BD	M-T271	232222	extra-cellular
	BV421	CD279/PD-1	BD	EH12.1	8345993	extra-cellular
	BV480	CD3	BD	UCHT1	7136608	extra-cellular
	BV605	CD38	BD	HIT2	9072931	extra-cellular
	BUV496	CD4	BD	SK3	9080989	extra-cellular
	Krome Orange	CD45	Beckman Coulter	J33	3	extra-cellular

	AF700	CD45RA	BD	HI100	9280346	intra-cellular
	BUV661	CD56	BD	NCAM16.2	148111	extra-cellular
	BV750	CD62L	BD	SK11	160192	extra-cellular
	BUV805	CD8	BD	SK1	126959	extra-cellular
	PE-Cy5.5	Eomes	ThermoFischer	WD1928	2195328	intra-cellular
	FITC	Foxp3	Invitrogen	PCH101	430002	intra-cellular
	BB700	GATA3	BD	L50-823	63599	intra-cellular
	PE-CF594	Granzyme B	BD	GB11	8165849	intra-cellular
	BUV563	HLA-DR	BD	G46-6	14801	extra-cellular
	BUV737	CD278/ICOS	BD	DX29	154933	extra-cellular
	PerCp-eFluor 710	RORgt	Invitrogen	AFKJS-9	2140726	intra-cellular
	Pacific Blue	T-bet	BioLegend	4B10	B307585	intra-cellular
	AF647	TCF-1	BioLegend	7F11A10	B281714	intra-cellular
B cell panel	BUV395	CD3	BD	UCHT1	9058566	Extra-cellular
	BUV496	CD38	BD	HIT2	115136	Extra-cellular
	BUV563	CD14	BD	M5E2	9294792	Extra-cellular
	BUV737	CD268	BD	11C1	148102	Extra-cellular
	BUV805	CD45	BD	HI30	8290565	Extra-cellular
	BV421	CD307e/FCRL5	BD	509F6	148106	Extra-cellular
	Pacific Blue	CD11c	Biolegend	3.9	B212042	Extra-cellular
	BV510	CD185/CXCR5	BD	RF8B2	9102753	Extra-cellular
	BV605	CD267	BD	1A1-K21-M22	148083	Extra-cellular
	BV650	CD24	BD	ML5	9141806	Extra-cellular
	BV711	CD86	BD	2331	9058846	Extra-cellular
	BV785	CD274/PD-L1	BD	MIH1	8262672	Extra-cellular
	BB515	CD95	BD	DX2	9093982	Extra-cellular
	FITC	IgD	BD	IA6-2	6288863	Extra-cellular
	PerCp-Cy5.5	CD279/PD-1	BD	EH12.1	2188652	Extra-cellular
	PE	CD10	BD	HI10 α	9123907	Extra-cellular
	PE-CF594	CD19	BD	HIB19	9128972	Extra-cellular
	PE-Cy7	CD27	BD	M-T271	232222	Extra-cellular
	APC	CD21	BD	B-ly4	52239	Extra-cellular
	AF6747	CD196/CCR6	BD	11A9	12938	Extra-cellular
APC-R700	CD40	BD	5C3	8819	Extra-cellular	
APC-Vio770	CD20	Miltenyi	REA780	5190430197	Extra-cellular	

1760

1761

1762

1763




Figure 1




Figure 2






Figure 3


A.



B.



C.



D.






Figure 4


A.




B.




C.




D.



E.



F.



G.




Figure 5




Figure 6

Discovery cohort							
Cancer patients' characteristics		Cancer_FR1_TR+ Cancer_FR1_CR+ Cancer_FR3 (n=110)	Ct>25 & ALC>800 (n=36)	Ct>25 & ALC<800 (n=22)	Ct<25 & ALC>800 (n=29)	Ct<25 & ALC<800 (n=23)	P
Age (year)	Median (range)	62 (13-95)	62 (13-82)	63 (20-83)	59 (38-95)	60 (21-84)	0.76 [#]
Gender–no(%)	Male	46 (42)	18 (50)	9 (41)	13 (45)	6 (26)	0.33
	Female	64 (58)	18 (50)	13 (59)	16 (55)	17 (74)	
Number of comorbidities –no(%) ^o	0	38 (45)	10 (45)	5 (34)	10 (38)	13 (62)	0.26
	1	25 (30)	5 (23)	6 (40)	10 (38)	4 (19)	
	2	16 (19)	4 (18)	2 (13)	6 (24)	4 (19)	
	3	5 (6)	3 (14)	2 (13)	0 (0)	0 (0)	
Comorbidities –no(%) ^o	COPD	6 (7)	2 (9)	1 (7)	1 (4)	2 (10)	0.98
	BMI ≥ 30	12 (14)	2 (9)	3 (20)	4 (15)	3 (14)	
	Hypertension	32 (38)	11 (50)	7 (47)	8 (31)	6 (29)	
	Congestive heart failure	3 (6)	1 (5)	1 (7)	1 (4)	0 (0)	
	Diabetes mellitus	10 (12)	3 (14)	1 (7)	4 (15)	2 (10)	
Type of malignancy –no(%)	S	92 (84)	33 (92)	15 (68)	26 (90)	18 (78)	0.08
	H	18 (16)	3 (8)	7 (32)	3 (10)	5 (22)	
Cancer spread –no(%)	Localized	19 (17)	7 (19)	1 (5)	7 (24)	4 (17)	0.46
	Locally advanced	24 (22)	9 (25)	6 (27)	3 (10)	6 (26)	
	Metastatic	67 (61)	20 (56)	15 (68)	19 (66)	13 (57)	
Cancer status –no(%)	Remission or NED	29 (26)	12 (30)	3 (14)	10 (34)	4 (17)	0.21
	SD/PD	47 (43)	17 (47)	11 (50)	11 (38)	8 (35)	
	Present or PD	34 (31)	7 (19)	8 (36)	8 (28)	11 (48)	
ECOG PS– no(%)	0	28 (25)	13 (36)	5 (23)	5 (18)	5 (22)	0.01
	1	46 (42)	18 (50)	4 (18)	12 (41)	12 (52)	
	2 or more	36 (33)	5 (14)	13 (59)	12 (41)	6 (26)	
Type of anticancer therapy– no(%)	None*	53 (48)	20 (56)	8 (36)	14 (48)	10 (43)	0.53
	Chemotherapy	47 (43)	4 (11)	12 (55)	11 (38)	14 (61)	
	Radiotherapy	8 (7)	2 (6)	3 (14)	1 (3)	2 (9)	
	Surgery	8 (7)	3 (8)	2 (9)	3 (10)	0 (0)	
	Hormonal therapy	11 (10)	4 (11)	0	4 (14)	3 (13)	
	Immunotherapy	12 (11)	4 (11)	1 (5)	4 (14)	3 (13)	
	Others	11 (10)	2 (6)	2 (9)	0 (0)	5 (22)	
Delay of treatment–no(%) ^o	Yes (range: 16-170 days)	12 (32)	2 (33)	2 (22)	8 (67)	0 (0)	<0.01
	No	26 (68)	4 (67)	7 (78)	4 (33)	11 (100)	
Clinical course –no(%) ^o	Day hospital	27 (32)	10 (45)	4 (27)	8 (31)	5 (24)	0.63
	Hospitalization	53 (63)	12 (55)	10 (67)	17 (65)	14 (67)	
	Admission to ICU	4 (5)	0	1 (6)	1 (4)	2 (9)	
Death–no(%)	Yes	31 (28)	4 (11)	7 (32)	9 (31)	11 (48)	0.02
Validation cohort							
Cancer patients' characteristics		Cancer_FR1_CR+ Cancer_FR3 (n=116)	Ct>25 & ALC>800 (n=22)	Ct>25 & ALC<800 (n=27)	Ct<25 & ALC>800 (n=29)	Ct<25 & ALC<800 (n=38)	P
Age (year)	Median (range)	65 (13-91)	55 (13-86)	64 (46-77)	68 (41-84)	66 (18-91)	0.09 [#]
Gender–no(%)	Male	71 (61)	9 (41)	14 (52)	17 (59)	23 (61)	0.48
	Female	45 (39)	13 (59)	13 (48)	12 (41)	15 (39)	
Type of malignancy –no(%)	S	85 (73)	19 (86)	19 (70)	22 (76)	25 (66)	0.36
	H	31 (27)	3 (14)	8 (30)	7 (24)	13 (34)	
Cancer spread –no(%)	Localized	9 (8)	3 (14)	1 (4)	3 (10)	2 (5.3)	0.40
	Locally advanced	15 (13)	4 (18)	6 (22)	3 (10)	2 (5.3)	
	Metastatic	82 (70)	15 (68)	17 (63)	21 (72)	29 (76.4)	
	Unknown	10 (9)	0 (0)	3 (11)	2 (8)	5 (13)	
Type of anticancer therapy– no(%) ^{o*}	None*	33 (36)	14 (74)	8 (36)	5 (23)	6 (21)	0.001
	Chemotherapy	28 (31)	1 (5)	11 (50)	5 (23)	11 (39)	
	Radiotherapy	5 (5)	0 (0)	2 (9)	1 (5)	2 (7)	
	Surgery	1 (1)	0 (0)	0 (0)	1 (5)	0 (0)	
	Hormonal therapy	4 (4)	2 (11)	1 (5)	0 (0)	1 (4)	
	Immunotherapy	20 (22)	2 (11)	2 (9)	6 (27)	10 (36)	
	Others	17 (19)	1 (5)	4 (18)	5 (23)	7 (25)	
Death–no(%)	Yes	27 (23)	1 (4)	5 (18)	6 (21)	15 (39)	0.016